var title_f6_54_7008="Choledochocele";
var content_f6_54_7008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choledochocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 311px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE3AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dkbLZzTA2c9KRjk/jSD60AKDzwe9OzUQ69e9OY+9AAfu9e9NJzQfu0lADz169qUngUw0vpQA/PSlB4PSmH0pccUAPHfmlX+lNHUinovpQA9T059qlGdvU0iR8Cvb/g58CtS8YJHqevGbTdFyCgK4lnHsD0HvQBwvw0+H2rePdcjstNiaO2HM126ny41+vc+1fbXw1+HGheANPMOkw77uRQJ7qTl5D/Qe1dD4d0LTfDmlQado1rHbWkKhVVR19ye5rToAKKKKACiiigAooooAKKKrX8pihyAfqD0oA5Px1fMVWGOQhFPzYNeZXUv+kZJ+X65rsPFUoLEgnnt1xXnt5I/mFgTnptx1oAV7jYACPlzn61m6hdIpUlyMnjJpkrNPsOSAGyx9KjuUEvDxkp0P+NAGVdRS3N0pWUsC3OO1dRBa75+SqlFUcHgVFZWSxAHbhOpBHartwqpOzQr8pAz+VAB5kivszkJ0PrU8TCSPIO79KqWszeaSVXbjg9zWjZKNrMeeeABQBDHtIBzvYnFdJougy3p8za+zPU1qeD/C5v5ftF0pSBD0I+9XfXiW2nWR2qkcaDigDm7Pw9aWtkJGQM4GcmtI3NlZJwyIB+Yri9c8VlnKQnanQ4rlLnVJLqQhXZ8HpmgD0jUvGljazBEbLEYUjrWdJ48aRcRKQPU9685lQM6MThxySeTU0GWtvkfLFumP5UAdr/wntxFIy+WSoxnjj860bXxl50g3JkkcBelea3Es6SCBWBQgFsCtbTgpkQgDA6+9AHeN4z2lkWPgdec4rQ0bxWLmRkmUAYyuK83lJF5sUgZ5wav27GNg3Ix370Aer2erQzRlpMoR2qlLr5WXaIQFz1J61xIvpQgQucEc0+K53PksSM5oA7o65GpAdDyeMelFcZJeDzAOCvrRQB+fTHLc8UgGQeelKfTPueabycmgAIw2Mj8KUYyCx49utIp+v4UH6UAJ2opT93pz60n8qAA0vag4OMDoOeaUZK45wKAFHYcY9adgn8aAuQPSpo4x1NABGhJPFbnhfw5qniTVodN0Wzku7yXoiDgD1Y9h716R8Hfglq3jrbqGoM+m6GG/1zL+8nH+wD29zX2B4J8E6B4LsPsvh+wjt9wAklPzSSe7MeTQB5t8HPgTp3g9k1PxA0Op6wVG1CmYrc/7IPU+9e2ABQAoAA4AHalooAKKKKACiiigAoopHZUUs5CqOpNAC0EgdTXIa54qaNzDp64IOPMYcGp9M1SWWJPMbJb7xJ6UAdMXHzYIyKx9ScyQt5jcex4NBuwqEFslv1FZeo3QZGU4UnqetAHKeIMFHZCM+hrzq4ci5cTSEEn5SD09a9B1yUbWCjI9cV5Tr1w66gCcKC2NpoAmT52LI6vgkY9RUgA3xkBSfTPQ1jtNsQhCd7MOh7f0p1tqKr87ElvuZxigDoRcSvKoj2lieTjjFamwXb+WzpGx5DHgD61ytozeespcnb1APFbccqbC8bNnOTx1oA0kXE6AAfL3HSut8FaAdSuTLMoEC8nArk9Kje7mjWJSQzjI9a920OwTTtOihQYO0FvrQBaxDZ238McSD8q848ceIjcKIoG2oOMev1rq/G939m0krnBc+vpXieozmXrKgJfnPXFAEF07s7M5Cqe2earwrtVZASz7uMtjH1qGVEmBjR90ijPPeooBIse2THoOaANRvLE6KxXzG+6uaWEskp3MGYHscCqNuQDIVcGQDjcMH8KsHd9mDOzBmGOnNAFhp0WZkTh27nn8qlgn8u42mQgDk8/oKyrl3jkQKGZxjjOMitONQ5UsFLHigDW3CUF4wAx4ye9OhZlUb8YIGPcVnSTCLaIwSwJ5pPtRjZfM+uKAN5pVjXG4k46Gnxz7BwcEdhXOtfuXJyBnqR2pftO6RRE3DElzmgDoPtaydPlHY0VlrPGgVWcDviigD4pYfSjtQfekoAKUdKTvRQAY4pKWjjFABTlXPamnk13fwn+Hup/EHX1sNOHlWyENc3TDKxL/AFPoKAOf0DQ9R1y/jsdHsZ728k+7FCpY/U+g+tfUnwd/Z2j0+WLVvHaw3FwuGj09TuRD6uf4j7dK9o+HvgLQ/AmkJZ6LbKJCB51y4zJMfVj/AE6V1lADIYo4YkihRY40GFVRgAegFPoooAKKKKACiiigAooJwMngVxnirxxaaWrRWLpPcDgsDlU/xoA6HW9Zs9HtzJdyANj5UB+Zq8/1HxJe6meTsgz9xRxXFz6tLrF5I95cNJJI2RxgCtRLjyYumSeMdqALM11mUIGUsBnitLTLwlztOGA9eprkru52SljwvU+1aOjXSyKx3AjtQB3Edy7hg0gAYcf4VTum4YKSSOKo20pfAXOB+lWWkHIJ57+lAGPqBJJwPl/WvKfGp2Xyk8NjrXrd8dyZAx7V5L8R4jAysuNpOC2cE+1AGBE8giZtwG7jB9qhaTCAnnuWOcg1WWGeQRt/yzHHH8jV1onMW8MoAxz1B9qAN3S7yMWZiDbm4Oc8itOG6WRkIxGvAIYdfpXKWdxDCkmzaHIwM9609EE2q3gSGKRucbgM45oA9q+F2mLNc+e3McZyD2NesdK5XwBpv2HRog4O/FaPijV49J055XbBwfwoA8/+KGsA3ZhDDanyjBrzeM+ZCWIBXdnHc1F4m1lr+9muAwKdRk4x/jVWG5EMAG7PG4tigCxIxFw8oU5VTjtmqkt20snAyTj2/Kq81+S2Hf5XHVPSoIbnDRuQxOcEelAGoXKqJWk2jutWLO/RmV3cNGD2PFZM7yT/ADTYVF/u8VWnaNIwbeMhPr+tAHSzzQ3F0pikRtx59quS3CRzNuIUYxnPFcQty6S7lYjackVflv45SNzng8AHGRQBqXl45Y+WflXhvTHqKms7hTlt+XHHJ7dhWZHOm3MjKse4ZP4frUb3kW/bEGBI4Hc+9AG28oYkgETA9PWmCVjlF4Ct9B9KzPPkf96/mhgNoOcZqWG/wMSDYi9GbjPtQBuROGKK2Mg84PTFFUUuUVQ+d2449s0UAfJ2eaQ9aDRQAGjtQKKACig1p6Hol7rVw8VhC0vloZZCBwijqSaAKVrCZplXOF7n0r7X+CK23hLwZpC2dq6LesHmdl+Zye5r5B0lo7W6DGLeoOMY5b2r71+EEcmoeBdKudUtFjlVcxoy/dHagDvwcgGiiigAooooAKKKKACq2o31tp1pJdXsyQwIMszHFcx8QfH+j+CrAyX86PdsP3VsrfM5/oK+WPH3xO1nxldlJJTDZD7sEfAX6+tAHq/jH4uvq18+l6DhICdpcnBcf0rhrO9ZZGWYuzMx471wWj+dFJHI8gbzDkDoT9K7zQLXzpHuHdjhsAZ5FAHTaWFhiM2OGHGTS3t5MX4UAg5BXvkU+WeJLTyUUAAZV/SuXuNRRzLulJeMgDA4/OgC1qEsxRjNIQD1x1Wt/wAMXiyxYTkD5Sa4q6uvORlm3DK9c9frW54IkVonxI7qrY5PWgD0iwkJIw2cDANX1cSDyyvA71lWJYRjAHPQ1o27AEbsknvQBXuU4I5BPAryf4q/LbR/KSwbBNeu3SAZIOO4rzD4nRRssLMMnPT1oA80XUJ9qJbw+Wka/MWOd3qaW+vCbDbBydwBxS2tu8s7rbp5kznaoGePwr0/wX4BDLFLqgBJwRHjgfWgDgvBOk6hrN55aQtt7s44Ar6K8GeFYNItEBCh+pLdzV7RdEstNhxDEiDr8oq5f6xbWStI7gfWgDfOoQ2qEZ7evQ1438VPFsd7aSWVvICScHDVQ8a/EMPI9ppu53kbaXXoK84mkd133Lh2Htz1oAtQossipIMuRzycVNG7QMyx5+XKlgeSKiidj94+XEBk46ini4jZiQQqYPKjpQBXiMhdhJGFXHynGf0q3AhjtmV8OSc7sVTiffcMoJLOOMHpx1p/mSRFEQkFcggetAD3PkzI7Myqw5HXBqtIdxcxnKt746U65ytvumdTM78gDBHvVSQfa3XZKV2jJ7UARXN0PtA37gOhAGcHFWbVxuQ8sjcdORVJoIzOGdyMcdc1O0jwTIi52nkZGc+9AGjd+Xv3yOTgYBI/pTIrsRAY6jqTzVBnYKy7iWI/HHerNnDudAWCt13Lxn2oA1ZJHlCiNNuCGyTxSXBLRrG5Uq2HJx6U+2dklVZAMJ146/jUsK5myWBjPA+Xj16UASwswtwSylQf8iioLmREnVI2XBPGRwaKAPmg0UHr0ooAKKKtabZT6jfQWdnE0txMwREUZJJoAm0TS7jWNSt7K0UGWZgoyeB7mvoXX7XSvhf8Phb2WH1O9URySfxSHv8AQVg/8Kk1fwxoaalJIgvAN7IvVABng9zWh8I/COq/FHxGL3xIZjpNlxGJF+VyO309aAOw/Z28IWHiKOLWNX0qNVTLQKy5Vv8Aar6YURW0SqoSKNeAOABXl/xH8UaZ8JfCay2kaG6f93b244BPsOwryP4WeOvF3xL8Y/Z72XNnH87pGCFQZoA+sKKRF2oq5zgYzS0AFFFYvi7xRpHhLR5dS168jtbZBxuPzOfRR3NAGxI6RRs8jKiKMlmOABXgPxZ/aE03RhcaZ4QKX+oDKPdf8soj7f3jXh/xe+Mus+OL+aG0nmsNCHyx2qNtMg9XI6k+leUGbJ4xQB0Oq61f63qEl7ql1Jc3Mhyzu2adYXJik3gluMY7YrCifPAPatDTlZ5MICc/rQB3GhQPKUlGWbGU55X8K9I0G3aG2aWfIZx0z+tYng6xgt7GGaZyszDgEZrT1C7llEriRVgJwcdqAF1u8zEYVfYqnDke9U3jFrFGFAaKQ8Hrn3qpDNH9nnVzlx0wOvNLNdiOAJGuQpz85yQaAK+p3cbboypTGDg/xe9dh4HtHSEuCCCfr/8AqrhNREaugeRH3AcDrk9q9S8FQRx6dEAp+b+dAHW2gby8468VoQrtCkDnpg96rW0ZEfLd+OOtWAjKCehB6ZoAjuw2CR07CvIviDJLJrtvaxcu4IC969WunIYnHOOvpXN6foyXniKa+nXcygJHkdKAKHgXwmlg32q4QNcN04+6PavRodkGCKgCeRByADjiuS8V+K49LTaCHnPAUH9aANTxR4zt9HtyGIMx+VUB7+9eL694tu9fuVSSRo03EYQ4A+tZeq3dzqd9NcyvufdjB/TFRGBIjEdoDc7mHIz3oAtCSNpUWPLN7N0qaRnRxHINyqOKq27w2swaYqqHJB6ZNRXGu27OVCgcZGfWgDZjcCIhG4PBJHQU2JJmlVYQCSMnHSsa41TaoZM71HHpWYuvTpkMSrEHbigDqr60u7PY8oysh4wKjiePzTlyoPc5HNZela091OBNOz/KSN3IBrUCy7BmP5uQdw7UAQX3mCVBC6t83zKwJz9KmEoBMXlbSPXp/wDXqndanHbagnlqdgQAketIt7C7jzHU85z6UAWLgKZVEo2sx+Ue1TX0ZWQ7U5CcEHvVaWRJruLyQSqMBnv/APqrVuklBJxlMfjQBmRwSoo3sPN68c1ftmMbxo7ANngY5NXFRYbQnAIP/LTHeqSOhuYg6u7DJ49+hoA1THIVQFcpu+bjJ+tE926QKihQ+Mowq5aXbFTC7Ywep6GodVeO1VQiIWf/ADzQBUsfM+0bmjIVhyCc5/woqzbSpHbgSHcz9qKAPmdupptSOpBINMoAAMmvRvgzqNtofiNL+eJJJQNsZf8Agz1I964Owtnup1jjQs7HAA6mu38J6IsWrhdRUrk7Y0JwS1AH054M8Tp8Rtfl0uKE/ZbMfvZOxFez2lpY6HppSBI7a1hUsx6ADuTXG/BrwZZ+FPD3mQRFbq8w8rt1NZ/x9vbibwdc6NpUpXULwbRtPOPT8aAPnD4jX2ofFn4oPZ6Q7TWschihz91VB5avqH4Q+B9P8CaD9kgQC7kw08rfec/WuU+AXwsfwjo7X2qIo1W5AJP9wdhVn49/EO38H6WljABLqs6/uV7r/tGgDsfEvjvS9Luk0+3uYptTlOFiU5I9zXSWdw402Oe/KRts3uegAr5u+D/gq4jvF8U+I5JGu7k71WQ5IB71V/aA+MyzafceH/Ds212PlzzIeg7ge9AG78Qf2ltP0u7urDwvp5vp4mMf2mZtsW4dwOpr5g8aeM9Z8X6m9/r99LdTEnYmcJGPRV6CudeQlj1596iyKABnJ60Ic45pO/Y1Zt4Q2MigC1Y2rTSKqAknsK7bRLWDTXhnu4z8gywIrO0e7tdPQOIw06jKkjIFQvfSXQcyNtD/AK0Ad9pOuDUJ3itkZEznA6Vq3pQ2Uyw4ZzzljjB9q870K5+zOXUknODjgHNdo++4s3kUp5YwGxk0AG3MKs4Bkxk4PH0pEnAdmLKQQdyj+Gls1ZLYsq8nJP0pl3abrNhnbJnnZ3FAFWKRbidCNsYQ5O8da9n8K4NnFtAxtHToa8csNPaS+jjDKdwALE/0r2zw1afZrRELcgYxnNAHS2qHYMngnnFTzxlFJHOaW22iHkHjtVa4ugEYN8vvQBXuMr97nPWn6U8TEY6jvWDqupeTA7b+Oe1V9C1CB4d6TZ3ZAyep70AbfjPV003SpZzliFOAtfMeueJZb67klYsZG9Ole7eLlN1o84O9gVOOfavl29ke3vZI2BUqxFAHUaZqy5P2zOGOSVqxc6sdvloMx7sjb7etchDcbyFIzTpLjMTBWICjGPWgC9qWrysnlk4Gc5HU1mC8LDe+SR0JPNUZ5N/LE561XaQkUAbiXzOmGbrzzVhSqojs5J9Otc8sxGP51oW026IAnHPegDZsblPtBZWMZAz65ravdV8yNFiuJmkOM5Pyj2FcmkgUE5IHSpYj8vP5Z6UAab3CclzlgOCv9aksbhZZG5CtjJz0FYLbgxHOT0xUsb4K4FAHWR3JtYknSbdKx+6G/Q1upr4ljVmAjYjGK4GGcLJ84GDwADjFaDXrRyxKDESDjCjO3mgD0GC6K20hcEocZycZ9hVnTlilkAfA3H7+Og9BXDm7mubXY7M21toAPIrd0i5dbdlkZVVcAEHJNAHVSWbROFQhkDj7vcVQ1+3upmHljKghRgdKorrMkEYWMfO7DG45rbt9R+2QEfdYDOB0FAFLTLOR1WCfc7BvlPpRXQaJp8s1yrpxnnJNFAHy7fW5jlZSCCDVPbzXS61Gn2yQAhvmOTisdYczY7k9KAPfP2X/AAQmo22r+IL22EkcC+VBuXPzdSRXc2fw3s9f8Z2d0Lkxtby72iUDacc16R8JdEXw18I7K3gXE7W5lfd3dqm+F3hWXSftWpX8jPc3TFlBOQo9qAO+giWGFIk+6ihR+FeYJ4L1W8+Jsmp6ldCXTYz5iR4/IV6izKgy7BR6k4paAGyusUbPIwVFGST2FeSeM/BWieMPGNnq91Gzrb4UknAbHTius8WeNtK0jWLbRbp1NxdD7pPQUnja/tfDfgDUdVCKRBAZU92xxQB4v8efidZeHbCTQfD0gbU2XYzr0gX/AB9K+Tp5mlZmkYszHJJ6k1Z1vUp9V1K5vbty887mR2Pck1nUAKSaBzSUCgByjjtV22z17VQzU8UhAHODQBqBiclzggVPBl8bW4AqjC+RlutWrQowbkAdaANzTZU3jfhQpBPHBrrbTWIo7SZI2TnsRXnX2o8hDxV21uFMeDjJ60AdvPrlvbugjYtvwOBxUcutyTSFkIwCeAOv1rjZJGkk46L0PerZnW2RT1JHU80AdHb301z4ltjG/wAuzHHHfmvc/D8hS1BLbvx6V4J4HK3fiGJcA7l4+te9aXCyWyq/D7egHbtQBvpdSCLAODjrVS9mG05zyKRd4iCtxjpVPUpCIXfAYhTigDkfF2rm0sJWZlYjPFee+FPHD/2itrNGvlZ4I7Gr3xL1JbbSnhKHdIR8x9a8p0ab/iZxt6mgD6iS8a8smOQoZcbfw6183+P7f7J4ku48EANkV7T4evfLiiRnBQpyCec15r8ZbeFdXt7mJixlj+Yn2NAHAwvg8kGrK5OMdCazo3AP/wBapopAWGT07UAJdNlsDGKrbiB0qWYDeSTxUBxtoAlVTtOau2ZGAXPHpWeGO3H61ZtsswwaANQENJ8jBvwqR22qecCq0QaNjgckU1mJ496AJVIJPIB7Y7U75owSzcdsdqg3BclsH2xUpk6YQYHrQBKJDkfXnNWt5MW/eAwPKgVnbsuC3TNXokMgJGOBzQBtWDoto7BlDMwGTWtpqCNXNuSVJPzdc8Vz9tHGI1RPmI6g9vpXS29xJHZC2sVURv8A6wkYGRQASeZkMxO88bRXS6TbXFwcNty4wpT+HFYlhaNcLnBB4GB+ua6+DUrLw3Zj7XhyV4yc/lQB3Hh9EgtIkndSV/i9aK8oHi+a+vwYSFiLbQvTiigDy7WiDcySc/O2aTwtZNqfiLT7SMZaadFxjrzVnxJDi9YKAuOcA5rvf2ZNHXVPifaPIqtHaqZSD69qAPrXXfO0bwLHFFGXlRETaK0vBstzNocT3Ywx6A9hWs+ySQxSoCOoyMg1KiKihUAVR0AoA+ff2g/GeoWHi3QNE06aSISyqz7eNwyBj9a9v0S9Emhw3EzABI/mY+w615d8QvAsviL4r6LfmJ3ht13En7v1/Ouz+Ijf2N8NtW8hiPKtmAYcdjQB4nrGvaH4q+I8t5BPFJJaMdp+laH7Qnjm0j+GP9lxuGnukEYGeT6n6V498GfDF9f+IEvQHRSDjjrmof2kQtn4pstMRifs9sC31JP+FAHkTHJptFFAC0UlFABSjikpaAJjKcAA1JFM2wgGqtKvWgC/E/BNW7eRgDhsY9qzY3wDj0qzbHc4BOPegDVjkKIS/XGaguJ3YjJ49KSZlEYHf3NV2YdAetAHoXwmQS62CUywxzivdvPC4KggjjNeQfCKOSOYEp8rEAccmvX2RU3eZnr3FAEv2gMSzOSfWq19cqUIBAJzjmiWaKNWGVbHPHpXO+ItUWK1kdCiEcjeeOKAPIvi/c41aO3RmIVdzZ9TXB6a5F5Hjrnir/inUZdU1SaeZtxJwD7Vm6YN17CMEksBigD3rw9AbjTY53DBmX72PwrB+K+kyT6bDcQ8pDwRjnnvXf8Ag+GD+zYQwxlfukcVc1yxSexmiaNWG0gnHGMUAfKHKsc5zUkI+YkE1Y1OFYtQnVegY4/Oq6fKuc0AK4zyxPNQkeh4p4BPJ6UkgwoxQAKDyM1ZtDhh3NV0BI6dKtW2BjH3vWgC+7HPJGQKq7jnqfxq6Y8IS7Dp3qi+c59KAHEkDnPSpFOVOevaoBllOfrmpFUE49qAHgE8noavQsVbCcgjoapKORkHryKvxquVABH05oA1tOwztLwCnOTXSaXbyXEETBDHESGYZ+81Z/h/TGmhld1xGcMR64q4+rpaIYI12z5zuznGKALviHXU0izVLUoJg33e4+tcDf6rPfM0lzIzbjnk1U1i6a4vJHZy5ZieaobxgBjxmgDXtNTkhUCI45/GiskMpHHWigDpbyFLiVSWC7jyTXuX7JVlbweJdZYANKIgA3pzXzvPeNKG2cbelerfsz+Jk0LxVfeeyj7REAu49xQB9r0Vx2h+IJb+SJhKGDyYK+1djQAYGc96yPF0ME/hrUI7oKYWiO4MMiteqesQxz6XdRzY8toznNAHj3wTms728lisrY+RbOVEhXA49K+b/wBpZ1f4oX+H3NtXPt7V9a+EIBaJdJpUCxrg5Kr+tfEfxZF1/wAJ/rX25mab7Q3LemeP0xQBx9FLSUAFLRRQAlFFFAC0Z5zRRQBJGatQEFhjrmqS96sRZBGOtAF6RuDk9qYmCy559qHYFAD96rmhWZvtRggTqzYNAHu3wqytkivCCQARkdPxrudTniEThQCwB+UnGa5nwjZQ6cMRHkYHXrxWhql5F5U0bAsxHy460AUbu6ja1Zkym1fmXOcfj3ryz4hawWhWKJivJBANdtc3Pl6ZdRF8p/ER249a8T8UXrXV65DErk4+lAGQ5yTnvVnQIy+r2yg4y459KpDmt/wTa/adftkAOC2eKAPozwzA40uIkDy2XAetDVXZLUABmDLyeh/GrmjqRp0MJJEaD5UIxioNfBS0kzgAKenpQB8ueI4C+u3YSMr+8PA+tZM6EOEx0FdHc3Qh1C7bCszMeSMkc1gXO55CWxnHWgCsy4PenxrlAOc0xgOuasW65GPT0oAb5W0dKt2sYJGQTR5eRj0qxaRFcZyFxk0ATLGhdi5O08YFVJoCWwg4zjOa1La0M022NuvP4Uklv5Mux0BNAGQ8RU4IINKEO3BJGa0DB5jMcc46U54BG67uVxxigCvHAN44OPzOa6HQ9P8AOkXcpJByc8YFUreSPzI9seCeOtaVzqyWduRbZRjwSep9eaANrVrp7OMJbBRIoyCh4A964W9vSkzGR9zVDcalLJI5DsS3U5rJnYuS39aAFuLku+T61XaTJHWomySaUcAe/NAFqOQ4oqNBnpRQBcd8Nwx5qzodzNDqtu0BbzfMAXb1JzWW7kMT61ueB7mK38WaTNcgGJbmMtn03CgD7L+GEOo6ZpIn1hWkctkPtxtHavTdH12y1VmS2lDSJ1Wua8S6ndvbQ2el2e62liBEmMDpUvw98OT6Ust1dtmSUcDHTNAHaHORgcd6q6uM6bcZJA2EnFW6bLgRPu6YOaAPNvDuvEaybS2iEcZODv43V8wftTaEdN8fG8VNsN5HuH+8OD/Suy8d/FL/AIRzxpPa2tkZRE2GJOPyqh8ddUj8b+A9M122jIaFwHyOQCMfzxQB85Uo680MMHmkoAKKWkoAKKKKAFpKKKAFFSq+AMVETk0oNAF7dkDdgVv+D5fs2qRXABJU/KAK5sbnwSa6nwwi+bCqtiQ5NAHsnhrVHns5MRkOHPJGahvtY8vzMNn5SF45/wD1VkaBfGO3uQDiRSQwb+YqHUW32krA8KMkj3/pQBh+JNVeKxNuX4fLFu5z2rzG7lLzMe2etdDr91ueT5txBxmuXYkknFAD1OG45967/wCE1k8+t+aFO1B94dia4GNSe1ezfAy2Lm4bHAI5xQB7fp8SrbqCCWA6is/xREH0yU5IGw5xXQWsSpBhSucZxXJePPEraB4e1JZIYpRPEYlD9ie4oA+Z1t2nuLmQDKhj169azp4yHweMdq6jTbkRafKWiJL/AMVYvleY7s/JJJ570AZDLzzzmrdpGzcIOT7UqgHICjGauwFoFG5cA96AHxwkKAw5PHFXbVERmSUkZGB3qG3RZJM7gT2z3rQhhE11HIifKuAcjj3oAt6escMjOqMzKD8vrWXfzZuNw298gDpWg5AvHY8BQeRxmueuH/fE7SAScUAXVcBkx3GDjtV7V7Tygipkk+2BWJbyH7QAeCCMV6ZdWDXXh9JxGDIi7uOtAHn0SiJfmzknHPaqGpNub7wIq/qjsh5GCD3rAvHODjrQBE74PFRZJOexpjMx5xTkJx+tACNkN0xmmjBQg4B9afK+7oMYpqHK8/hxQBNDkAHAxminxg7VwKKAKsn3j61JaSmKdHzjBBFMYkmkBIPFAH6D/Drxzpt/8MrTVbiZcW8AWUHjkDmtDwX49svEcwjtWVkY4Rlr5A+F+uwTeG9V8O31y0UdyN0fPGe4r6M+Bngs6Pbw3ZmeQNhwCMD8KAPX9XumstNnuEALRruwar6RqCaxpfmqChZcMKvXkC3NpLA/3ZFK1R0c29qP7PhjEbwqMgd/egD5X+OHhK2t/FVtfT4WKR9sn+1XT3Gg22seBX0vSVWNHhxGOozitr9qC3gTw816U3SRMpAA79K5P4OeKotUNvbpDsMaBWHbNAHy/q9lNp2oT2l0hSeFyjr6EGqVe3/tK+D20nxH/bFvGRa3vLEdA/8A9cV4jQAlFLSUAFFFFABRRRQAUvbiinjJHvmgCVM5UAc11OgAre2hUZxzz0rAs4SzDPPNdr4Z02W51FAE2RqMkmgC5ayS/wBoTJCdxLABhXVX2i3n9iyGHO6UcleePSl0+wt7DUmmyNmRjd61b8SeNLXT7VI4sOwHCr2oA8b1nSbiK5MTg792CPek0/w+9xKEZgpx1Jpuua9NfX8ko+Xc27rVGLUp1YFXxigDtLPwI8ksSqzHf7fyr6C8AeBY9H0tBEH5XLH1NeU/Be/uNU1ULeHzI4h8pPY19S+H2FxGsYUeWvoO9AHOyxmDIEZOBivBvjpdTXFzaWUEbjJLYx1r63k0qGWNi4AI615/4u8K6dd3CPPHHIyZ2se1AHzBDo0kfh4blYuybsdMVx4ZkZkIwOlfSOradb6chtolUq/AJ7Vw2ueBBcsjWojRCN+VHWgDx6SJjIBGOtdM2nxppscrkFinT3qjqkLaddSW+MMp5OOa1LfUDJpohlRHYrwccigDDsZG3ldgY579q6jTbWaVg0ZC8bSCMZ/+vU3hDRY7wyzGTBwcDHWtZone5McJ2Rp1JoAxrywFqZJN+ZsfdA/SuPuuZScZyc/SvRdQRZrV3VdxVduR2Pqa4g2TmY+aMYzn1oAqabE0t9GEXccgkGvUoXktdEJciNxk89PpiuM8PwhL1HWEHae/WtzxZfoNNaMs3mcYUHigDj/EEwllkCqu3dngdK5K7bLY7VoXU5Dt8xP41mTSbnJBGKAI+3fNKpwCMig59qaKADvTl7Gk75p6HgHI45we9AEsbtxiikjz7UUARv14600HNPkBzUY5PNAF/SH231uC21TIoLDtzX37Z+JLTw74a0yGBfNby1+b8K/Pm3z5i44wa+/Pg1Hp/iP4aaRNOqTTJGEZjyQQMc/lQB3nh7VBq+nrchNhJwRVm5a3tXN1LhSRtLUun2kdlbCGIYUGnXlrFeQ+VcLuTIOPpQBkeKfDdh4l0ye2vYlkWZNvzdK8NtfA/wDwhesbbddsRfhB/jX0gAAAB0Fc3410xLywMoB81BxjqaAPMfjXo3/CR/DKVY1X7RFGJFz1JXmviOdCjkelfbiJfavG+mXrvbxuCn1U8V87fFn4W6h4TvZJreN59PYkq4GSns3+NAHlGKSpCpBOeoplACUCkpaACinKMnB4qzHBGyA5oAqj2qeFMkADrVmG0DEDPXpW/pmlQLGs0zD5T92gDW8GeHfteya4Q+SD+denww2lq29URNi4PA4FcJL4utLS1it7JW449MVLo+oz3n2yaS4LKVJ2460AZviHW5bnU5BC7RxKeFB61yesTMQdzHJ5wau3syh5GXhs55rCvpmlb5qAKRyWNTWsTSSKqjJJxikVM5wK9K+FnhN765F7PH+7Q/ICPvGgD0z4TeHxpelwuyFZn5YnvmvcvD0ogHykgj9TXKaNYpHGhKj5RjiumhdUgBXINAHQ32rolsQ2Q+Oa8o8YeM7GLU/svmjzsZ25rd8W6xHYabNcSuqqiE8nk18i61rc954imvizHdISKAPfPEFuNQ0kyFyHILh/7uBnmsHwf4r+1p/Z5j8tosqGY5z71J4c1F7/AMLFmYgyIcjPQ15bC1xb30jIzllZjwcfWgDrviD4ZScNqMZCELl8dD7/AFrifD9qZGd5kPkJ95vQeldXqmqXk3hZJU5YjDZ9Ky/DckskAWQp5R5x0LH0oA6fw00KIViXy056DpmrzWWZ5ACwDcj2rFtXa3vHBRQkjE4BwoFb0M8jFXRlIGAfmzQBzep7rbda2+Q8nJHXd9aqvp0UViHmUmfqyZ6e1b2r2KQ3iXkshcbSzY421hXGpR3EZEHJORnv7mgDPspY0ujJDGchTlQegrI8RX6yDCj5guCf61LeRNaK0gk2kjJIPI+tctf3DzO2TkUAZ87kuSKhPPpTpOtNHXpQA8rwM49ajA55qU9s0zHPSgBduO4NKo4FOCZFCg9KAJFHTminKhGMYooAjl6+hqMDvVpgC3vUb98jmgBsbAEV9K/sq+NotNlutHu3CwsplDM36CvmlQd4AAyavWlzLbOGhZkbpkHBoA/Qmw+Iei3d08SXMbbDhirA7a6+3niuYVlgdXjboQa/NzRNZuNP1FLmGVhz83PX619p/AXWLvWNAaac7o8cMBgE57UAepsQoJYgAdzUNzEJ41wcjOfrTdRtjd2UsAcoXGAwrL0iWaxX7FeNmUHCHrkUAUtX0eJi9xCAk6ndtryj4i+N7XR7C4TWI1mkkUrHDgfMa9z1KMiCSUDLBcYFePeKfhta+NLuK4vch424A4yPQ0AfIc/h/ULmC41C3sZms9xYuq5C1z0q7c1+iHhXwTbWWly6fc28Qt9mwBcHNfPPxq+BVxoaz6v4eHnWXLvB3Qe3+FAHzccUVNPEYycgioSMHmgBc1YgJYBRk1DEhkcKoyTXsXw0+HpuVgvr9TyciMjp9aAMLwV4IvtZeKaSNo7YkEE9SK9Y1HwDbNYpBHEVOOT0r0HQ9IitYVRECr2ArZayHlk4yfegD5V8YeBZ9H3SxEyRrycdRWRpt41hpE28lfN4AHU19P63o0V1A0c0eQe5FfM/xWCWevtZ26BY4VxgDHNAHP3lwpjJByW61nn5gSepqqJGY+uK1NGs5dQuYreEFnkYAACgDd8EeGZ9dvgUU+ShBYnofavpXwtoMen2CRqmCMAAVl/D7wtHpOmxIF/eFRvOOpr0mysisQ7ntmgAtoBHGuF+buKknmWOMDb+FaKWpPG7btHXtWB4inWzs55HOQqk596APDfjX4m+0XC6ZbScKd0hU/pXlEio1shVTuyQc10Ou3MlzqdzdtGrtIT8p7VmaHbtfXsdqVO2R8HAyaAPR/h3aTt4YkkuFwiA7SP61xbSJLqtzvYogLAAGvYIdMk0nw3JCpIzHtC+o9681XSVkkYRAKxbcR70AdRodjHqnhh4fKJ2qQqnoa5GOy+x3LxbCMcbv7vtXqfgC2iWwIkJGTwCKzfHGiSLMr2sRVM/vCo+970Acpb209w0ARdynIz2roNL0wAFWyhUbjn29KveG9MmhsiGhxHHnDsMZNLc3b21pIJwA7EhSOlAHOeMJom0x1EhVmGAM+/SuH0vbby5kjzGchiOcVu6mz6iD95VHb+tZTx/YopIt6uV5zz1oAyfFF5GRshUqvdSa5GWQbia09UnM0zswrHfuSKAGOwP40wECgnjpSD6UASlh15pARnrmgHgCkH0oAnVh680qHio4yM9KmyBgAUAPUjPOeaKkVdwBxRQBW28+496HXJ601mxjAppc7cZGOtADlA3cdfrU7ABR/jVQNhhgjNSmQ7Rjgj0oA1/C9lHqmvWNhNOsEU8yxtKTwoJr9GfCmj2Hh7QLLT9OVFt4o1AI/i461+ZcUhR1ZTgg5BBr6/+EnxWtD8PozrOoRC6tBscyN85A6EDvkUAfRopjQxvIsjIpdehxyK+e9N+OqP4kitoIWksZWA3kdPwr6AsbhLyzhuI8hZFDDNAD7jPkvtGWI4GM1Ss7L5N0y7G7AVo0UANjRY1CqMCo7y2iu7aSC4QPG4wQamooA+Mfj/8HpvD1zc61o8bPpjHe6Lzs9/pXgDRENiv1B1bTrfVdPms7uNXhlUqwIz1r5J8e/s/Xun66ZtGZW02RtwVhyvsPagDjPhP4HXUB9vvUzGMFAR196+hdD0tIIVEaKAe3rWL4U0WTSbOK2MZGxQMCu2s12hF24Hc4oA17CxURLkDdVia0V+gCge/WrunwBolYjIPGa0obIEBtv3elAHHanZAQMWBwARXyt8e9GaDWorsKQsq7c/Svs7V7XMLDAJ9q+bP2ibUf2bCxABV+maAPmtIGVyCpGOoNeu/BXRC9w168YY5wpPavPNMspNQu47e3RnkkbAwM19S/Dvw4mk6TBDjsC3HegDsdHttkaEryAM10lrAz7gV57VFY2oaJTt5+lbdrD5YG9R0xkUAV5Y8jBXBxXlfxcvHtdEnihb97Mdgx6d69fu1URljjIHFeFfFWeOaaO3MgJDZ68igDxWXTppo9ysd+doHSup8A+F5Ir8XF4oQocqpoEqW7B1UHauSMd66fwxePNaLNcZKknG2gDS8dTGHRH2yBQ4wOfWvPPDVtnIaT5+2O9W/idqT4ity7LC2ScHmuO07VzAnlwZYkZJHrQB6fpurJY31vFIT5YbaV7iu/uXhmiVshgwyBivBbTUzPfI0/BA4YnmvVbfU44bCGVmD5XAPTHFADtR1FrW3KGPEZJyq1h3iRX0ZbaQXAAyeD71Q13UWltpH3D7nY/dNVPDchuo085thVOgPJoAq3hiFzJCAq4HfjP0rA19ituQEG5xxxyBVvxJexNdPGwIK9wK5LVdTklxCWU7c4bOKAOfvVJkcEcVnyx9T2q+8m9mz1NMuQPLJx1oAympMcU5xzSqMjpmgBcAY70oXIyO1SbMqOOadGM54FAEacc1Z8vKgjr9ahIwxGAKswncnSgB8XAwfWikHB/GigDOY8005NPOOOaQcZyaAI+9SE/L3pPTrTieMDpQBGcVoafcCN13crnkeorPNPRsGgD6N+BHha08V6tHKqfubchmz/CRX17bQpb28cMQwiKFA9q+A/g98Sb3wDraSxYl0+ZgLiI9x6j3r7v8AD2s2XiDR7bUtNlWW2nQMrA9PY0AaNFFFABRRRQAUjorqVcBh6GlooA4zUtHUXxaNeS3zYHatK10NFfcVXgcGt8xoTkqCacBQBUt7VY4xGVAAOeO9WscYpaKAM2/iOz5gPrmvEPjF4d/tm0EPP3s9K94vEBTnmvOvE8iy3uw8nOCuKAPI/A/w9stGv4rht0kwB6jHavYdGgReAMAn0rKtID5owvTPWt23nWMKBgHtigDpLQrHuUjAI44p0t0iIVZuBWOb4iEccjrzWRquqrAjyySAccGgC14n1pbS1d2f5FHevnfV73+1tZmuJS5MjEKp4IA/pW9498RPfymKGQ+TjkA4zXMLKZIOFVTjAYdTQBm65LLCpjYDnuO9dh8N7hjpSx3Hzg5xXA6owlkVY8yN0wxPBrrob1dH0ZWYKku0YC+vpQBzHxduo21ZIYMfKM4HrXJ6PHJEHafaFK9Gq5ql1JealLPJnJzyRWekczKzg4IU4yaANKFxK6rgcgZOffoK765dU0+zjSRguMEHjmvN/D6l7lFABYt3r06VPLCiSEvGV2kY+6fUUAUxateWzR4KsRkZPUVV0aJLK5dFJYkkelb+m200dz8oL7l4Bp13aCOZjGuG3AjigDjNba2s5ZpbxTIHj4VTgk/WvLryXdMSM7SeBXf+PZs/Kn3R3PUmvOJCd2c0AOik+fmprmXzR+lVsgZPegvmgCF0IzTU4FWh8wI4zUW08ZoAmjCNC+9sMACo253HPT2pYlwSeoqS3hMrBFGTUlzC0LBBySKAIpYwDkUsQx361MoZogMHio41bcFAyaAJzCduR60VqQ2vlhGuDtU88jk0UAcswFN4p2R3pD1oAjHUdac2MdxQD/Djv1xzTj05oAiPA5pB2px6fjR0xQBZicDivZfgT8WbjwRqK2OoM0uiTth17xE/xCvFgQP61PFJg0AfpzpeoWuqWEN7YTJNbTKGR1OQQatV8HfC34v634Fzbxk3mnNz9nkbhfoe1fYHw08e6Z460SO8spES5AxNb7vmQ0AdjRRRQAUUUUAFFFFABTJc7Dt4bsafQehoAxNVvfIizuAOO9eIa/4kNv4q2SvlducjkV6P481iOySWSVwsca5y1fPl3rcN7rsV9gYbIx0GO1AHrdlq0LFW3cGrs2rW8al3kAQdD6mvINVvplMTx7k57VTm1qRrUE7nUEjHvQB6Rrvje1tomEDmWXOAqj+dcVrHiy4ucCVdoIyoHb6ismzhWWHfDjzkOWyfXtVS8XddLLHgkjBHoaAJdWMc5hfO1tu48cGk8wJYlYwOB2/WnzsrZBVd4Xlf8KYLaZ4E+UqHOAD3FAGbothJc6ssrD5Qo5PeqPjy/J1BbWAqIlxwDXS3rR6VbbjNyy/dBxivOtXvVvbzlVR+ckc7qANrSoIhJM0pATbk8g8VBPBZPZyeRK3+yMVkPJIluQjfw4OKu6Zg2khC/MEOAD1NADdIIS7Vc/MW/ECvZLK5je2jVow58vg+teO6QzLeogQb93U9jXf6NeqLho0I3BSpIPAoA6TTpiXeUsqBBxz71UvbsfbJBk4ZQxI5xWXOji4QDG0YzzwauDDmSaIOAVAYDvj+lAHK+LdPgvbGSVD+8QfL714/OcSMO+a9c8QXUUMM6EnzNvKjoCa8ovVxKxHc0AVG9M0nbNKcZ/Cmk4BoAejc5p69j7VCpHWrcMe5QQCRQBpWM6W6iTALYoS4jd2MgBJHHtVFjx9KjRufagDoDCihSoyrLVSzhY3ZG0jb3xWj4akjur6KG4YrHjAxzXc6hotjBpH2mIr5yqQ6Ecr6E0AcJfTGeRFYgBFAHvRUUcTSXTBDuooA5dhmgYz1p+cZyabvHIx+lADeCw6VOY1Kg5qANzxx+FTiUAfT2oAgcAKfrTM0+SQnPHeot9AEhI9RS78Dg1GW6cUpPHQ/lQBIJsGun8DeMNS8I65BqWkzskiMC6Z+WQdwa5TdTkfBwD+NAH6BfCH4saX8QrNkVRaapGP3lszZyPUHuK9Kr8ytB1m+0bUYb3S7mS3uYyCGjOM+x9q+4fgv8WNP8caVDbXkqQa3Gu2SInG/H8QoA9UooooAKKKKACo7hzHBI4UuVUnaO9SUUAfMnxrOqXZJCOlszEso/TNeaWlgw8vIbHXmvsLxv4eTXNKkSONTcLyuR972rwTVNHezuWivrcRKmOFHJ96AOXjZ5UKn54oQRkdabFEjNHGykxH5iAe9a8tutu37lW8qQ9MZz9af/Z6cchMkEkHP4UAYeFRZGhEiHPQdeKzgSbnbtY7mwuOK7JdIPkuVBVC+Qy/xUr2NnZonnCPzGJK5HK0AZdrpkhu4/OxtYZPFbUlpa2tqVBXfndjPNVkvy8nlCMdP8kVnalcFXVmbMYA/P0oA5jx3k3Eaq2Avc9DXAPs87d1IrvvFQN5arOoOV+XI5wK4byhG5LN8pJoAswBHgfJyWGfpVnTitsHZ8/MMcVUs9pwiE5x+HtU8SzhdroCqc8GgDXtEh+0rjaZGwR2Oa27BIrRX8xgm1iWXPUn1rF0MFpQy7STgK7Doa2LyOCN/IiuC8vVgRkf/AF6AOmtFtr+132ahjgHDH86tJHHBaXEbcFfu5HesXwQFt7zy5ZCA/wAowOK2vEc1tayMnmrIuPmAH8zQB5J4muZHv7hJzhh3Fcbcj3H1rrfFpjeUyq+SeMYrlSS6EcflQBQIAXrUYORUkrEZ44+lMDZ4x+lAAAMds1qabMgQxvjkYGaz0GR0HT0qWLjBHagC1dRlCcgVVC5J5rRhb7RtVup7kVFHbM0hCqcZxQA7T9yXCGM8j0r02W4aTRPIkYjcqliR7dq5vS7W1tlVm/eygcgcYNSXl6QxHzKmcZJzQB0HhPRrJp0+0bJSx3YzjFFVvDriO8hkXBUnAJOCfpRQB5MxYkDFIN3PSlzzjHelPB+6KAGrkHOOKcc0wZyOKcScdKAGtkDt1qM7s9O9PJOD8tMz6jvQAENxxSjcRS5/2e1BznpQAmW7UKTml/A8UgIz93FAEiEg1r6Dq17pGowXunzvBcREMrKcVjA89Klil2ngUAfevwe+Kdh4v0O3TULiKHVVAWRGONx9a9TByMivzIstQubaRJbaaSGRCCrIcEGvsr9n74oR+ItFi03WbhF1GEbQXOC/pQB7bRRRQAUUUUAFct450O11DT3uXRRPGODj71dTVbUkjkspVmICbeSe1AHz1d6ZPHllGVGRgcYHpUcGnGWNdse3Dc5rtddRYJmjjUvzwVHWs62RjvD/AHR3oAx9RlSzs9oXBU9ua5ozG4uStyqtEDuDEZI9hXS6nb+bDK2CWU8YrMtrQPaNvX5hzk9c96AKdvChk3IVJIwPrWJrELRRsGK4JJ9vpXWWtptPyEY4BzyKxvFEaQ223aQzZJx0xQBzAEFxZOowu1TlFPWvMbgObl1cNt5wD2r0nSNpu5Nh3kgqf9oVg6jpEk11JKUwWJzjjGKAMHSrUPOhkyIwMk+latyETcYSmxkxjOTmpzbxW5FvGrlnXDnHFVCqt+5SMMenJoA0dBgaFVeUlkzuIB/nVp/Kk1HdHnawyCP8ahSFbSxd5CrHZyv196y7CbM0Ic7ohklc0AdpbbbG1kuXBzjcCfb1rmr/AFyO/Z2kJVc4CdMe9Raxq8sWnNbxjaH9TnI9K4+4uTvVznI60ATXxUpLg7ucgmsSIld3Na7tG0TtH0I6ZrDlJWSgBkynce9CIasBS689amitjtyQeaAKqgqPfFTRJnAxVqO2VnGQQMc06YBSdgIUDigCIfu8bTnHPSrmnbnkZiSBVNAWwMHrzWzpsJWFpAACvY9DQBd3Rb45Fx5g54PU+9RXAkmcyEb19fSqTNIZ9hXa2a6HSIzFOqSoTI38PagDV8MW73F3EzrwpGMHoaK9M8MaVDY2sV1OkGxuVcHrRQB8pEcng4pfzoUMMgdO4FGPpQA0HvinH7uKaBg5qUgd6AISDt4Bpg9wetSP92me3vQApPAGOadnHY03HT0pQOTxxQAY+tNGPQ0/60wD1oAcuMnjtSDgng0cA9ulJ7e1AFmJ8LnmtXStUuNOu47izmeGdDlWU4rCXp0qVGIIoA+y/gZ8aLfWLeLSPEc6x3wIWKRjw4r35WDKGUgqRkEV+YdlcSRTI8TFZFOQwOCDX2f8AfiZb61o0GmavdIuoRgKN55agD26iimyOsaF3YKo5JPagB1Zuvqn2FnlkZVTnA71zuo+ObW31DZF80CZ3HpuP+FcrqHiltYv8l18kdEU8Ae9AEkubi54fKj0q29j5NoMoQW5wafpyRzufJj5HfNa2oWpEcfBboRk0AcZc2T7Dtxtz171ntZ4kdAuAefrXYy2JdwQDgn7oNZU2FmI29Bg/WgDANoqPhOAO1c/4yizaqi5aU9DjNd49sHXLRHaT2FUNW0wfZMqpPr9KAPJ9ItTDeKHUMrY4Pr3p/ia7gWUxW0YL7fnJFdFLYzR3AkERwH6MO3rXPaztn1B/NUxkD72PvUAc5GwvFJCqm3qe5q1a2UU92NiArt5z1NaCQRGTESqSBjb0x7kVraPpuxZJVwN64XNAHJeJYkaIRHaIwwBK1j2NvEt2I0jZgBkH0rsdZ06SK4jijXdk784zk1Ba6R5N+73B8sEdAMYoA5fXNK+z2au4ZjjI3dRmuKvoyHI969p8SPpsmmLHM42Bcrzg15RqGmu826DJiY8E0AY6xt5ZO7GRVObG8961rmPyEMRUbu+DWb5QduO1AC23XpxV7zB0UdKhjiK8AAE9609N08zli3QDqO59KAK6NsUk9cGoXYuo+XGRzVh4/3xVMY5qqoYscjgDpQBZs7YyuNvTvitaVJYIPKxyO4PrUvh+LbulK/u1GcetOvZhcXjAbcNyQOiigCnbxSTaigYZIwck9RXTi2e2DTuGClPlwelULFY1uQpTL4G0rzmuh1qJ4dGb5htJGBjnFAFODVrsXy20krmFeQC3AHaiqvhiyW+1VEkYsWHBNFAHlIJGR0zxSZoooARc54wak7AHGM0UUARPwKaOo4oooAce3SlNFFAAQemKaPbiiigBcewpAO2KKKABRxxU0URYjpRRQBft7fCk8ZFaWh6lcaXqUF1bOY5ImBBFFFAHumn/tD6ra21vDJFG+wYZiuSa0bf4yah4gci8AjtwcbI+BzRRQBXbW4dTut0O4RoDvznmsEeMSNUMFmoCKMEkEUUUAeu+CNf8ySNGUFGxzjkmvVHtlVN/XcuRnmiigDKkiVSCqgFmI3Vmzacr3BAwSBnPrRRQBGls8RKdAO1WILOOSLMyBkY+tFFAEa+GQ8clwApQA8E815x4p8KSTuzxMkakcrgfzoooA5fT9Bljuw87BsZUEV0un6eY4DkAgfrRRQBY+yQZ3kAL1IxXIeMbmOWGeMR7RjCsgwQaKKAPMbuFlnhE7u+0dzVO+1bIePaBGp4UDHNFFAHPzOJugP1NJDZmONpeox1zRRQBHCriXbn5Sc81rGV7dNu3BY9j3oooApiYhizEjcD0qO1XNwgPO7g0UUAegy6clnpBCsFYgFSVzjiuSS1YMzSP8gYg+tFFAHW6DbwkgklSo4bGePpW9qtubq3VIGVlAyd44oooAqeH7J7HUA5EZ3MGOB90CiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7008=[""].join("\n");
var outline_f6_54_7008=null;
var title_f6_54_7009="Abdominal aortic aneurysm long and short axis";
var content_f6_54_7009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm long and short axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The long axis view shows an aneurysm of the abdominal aorta (A Ao An) as the aorta crosses the diaphragm. Prominent plaques just beyond the aneurysm can be appreciated.",
"    <br>",
"     (B) The short axis through the aneurysm (An) also shows the inferior vena cava (IVC).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7009=[""].join("\n");
var outline_f6_54_7009=null;
var title_f6_54_7010="Laparoscopic resection of the crura of the diaphragm";
var content_f6_54_7010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic resection of the crura of the diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intraoperative photograph shows the Penrose drain around the esophagus. It serves to facilitate dissection of the posterior aspect of the paraesophageal hernia sac. The crura of the diaphragm have been completely dissected using the laparoscopic technique. The arrow indicates the Penrose drain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7010=[""].join("\n");
var outline_f6_54_7010=null;
var title_f6_54_7011="Rosacea papules and pustules";
var content_f6_54_7011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules and pustules are present on the nose and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7011=[""].join("\n");
var outline_f6_54_7011=null;
var title_f6_54_7012="Patient information: Coronary heart disease in women (The Basics)";
var content_f6_54_7012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85797\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8356\">",
"         Coronary heart disease",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3331\">",
"          Heart attack",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/58/37797\">",
"           Heart attack symptoms",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38004\">",
"            Coronary artery bypass graft surgery",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/30/32226\">",
"         Patient information: Nuclear heart testing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/45/4819\">",
"         Patient information: Pleuritic chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28642\">",
"         Patient information: Diet and health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Coronary heart disease in women (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2050649\">",
"      <span class=\"h1\">",
"       What is coronary heart disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Coronary heart disease, also called &ldquo;coronary artery disease,&rdquo; is 1 of the most common types of heart disease. It puts you at risk for a heart attack and other forms of heart disease. In coronary heart disease, the arteries that bring blood to the heart get clogged with fatty deposits (",
"      <a class=\"graphic graphic_figure graphicRef61785 \" href=\"UTD.htm?8/10/8356\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2050681\">",
"      <span class=\"h1\">",
"       Does coronary heart disease happen in women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. In fact, coronary heart disease is the most common cause of death in women in the United States. Women often worry about getting cancer, especially breast cancer, as they get older. But many more women die from heart disease than from breast cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2050696\">",
"      <span class=\"h1\">",
"       What are the symptoms of coronary heart disease in women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of coronary heart disease are often the same in both women and men. The most common symptom is some type of chest pain. Men usually describe their chest pain as a feeling of tightness in the chest. Women often say their chest pain feels sharp or burning. In men, symptoms are usually brought on by exercise. In women, symptoms can happen during rest or sleep. They can also be brought on by stress.",
"     </p>",
"     <p>",
"      Some women have no symptoms of coronary heart disease until they start to have a heart attack. A heart attack is when 1 of the arteries that bring blood to the heart gets blocked (",
"      <a class=\"graphic graphic_figure graphicRef60394 \" href=\"UTD.htm?3/16/3331\">",
"       figure 2",
"      </a>",
"      ). In women, the most common symptoms of a heart attack are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling weak",
"       </li>",
"       <li>",
"        Feeling much more tired than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These are different from the symptoms people usually think of when they think of someone having a heart attack. Sometimes, women also have these &ldquo;classic&rdquo; symptoms when they have a heart attack (",
"      <a class=\"graphic graphic_figure graphicRef85777 \" href=\"UTD.htm?36/58/37797\">",
"       figure 3",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain, pressure, or discomfort",
"       </li>",
"       <li>",
"        Pain in the neck, arm, throat, back, or other part of the body",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Sweating or having cold, clammy skin",
"       </li>",
"       <li>",
"        Racing heart",
"       </li>",
"       <li>",
"        Feeling dizzy or light-headed",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2050745\">",
"      <span class=\"h1\">",
"       Is there a test for coronary heart disease in women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tests to check for coronary heart disease are usually the same in women and men. They can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests, including tests to check cholesterol levels",
"       </li>",
"       <li>",
"        An electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in your heart.",
"       </li>",
"       <li>",
"        A stress test &ndash; During this test, a doctor records your ECG while you exercise on a treadmill or bike, or get medicine to make your heart pump faster.",
"       </li>",
"       <li>",
"        An echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create a picture of your heart as it beats.",
"       </li>",
"       <li>",
"        Nuclear heart testing &ndash; During this test, the doctor puts a small amount of radioactive material into your vein through a needle. Then a camera takes pictures of the heart.",
"       </li>",
"       <li>",
"        Cardiac catheterization (also known as &ldquo;cardiac cath&rdquo;) &ndash; During this test, a doctor puts a thin tube into a blood vessel in your leg and threads it up to your heart. When the tube is in place, he or she can do tests or unblock a clogged artery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <strong>",
"       How is coronary heart disease in women treated?",
"      </strong>",
"      &ndash; In general, coronary heart disease is treated the same in women and men. Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Different medicines &ndash; Some medicines relieve chest pain. These include nitrates, beta blockers, and others. Other medicines lower your risk of heart attacks and help you live longer. These include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Medicines called statins, which lower cholesterol",
"       </li>",
"       <li>",
"        Medicines to lower blood pressure",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         Aspirin",
"        </a>",
"        or other medicines that help prevent blood clots",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A procedure to reopen a clogged artery, called &ldquo;angioplasty&rdquo; or &ldquo;stenting&rdquo;",
"       </li>",
"       <li>",
"        Surgery to re-route blood around a clogged artery, called &ldquo;bypass surgery&rdquo; or &ldquo;coronary artery bypass grafting&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef73589 \" href=\"UTD.htm?37/7/38004\">",
"         figure 4",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2050783\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help prevent coronary heart disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help prevent coronary heart disease, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Work with your doctor to get medical conditions such as high blood pressure, high cholesterol, and diabetes under control.",
"       </li>",
"       <li>",
"        Stop smoking.",
"       </li>",
"       <li>",
"        Exercise at least 30 minutes a day, on most days of the week.",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight.",
"       </li>",
"       <li>",
"        Eat lots of fruits and vegetables and low-fat dairy products, and not a lot of meat or fatty foods.",
"       </li>",
"       <li>",
"        Limit your alcohol intake to no more than 1 drink a day.",
"       </li>",
"       <li>",
"        Get treated for depression, if you are depressed. Depression increases your chance of getting heart disease.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2050798\">",
"      <span class=\"h1\">",
"       Can taking hormones help prevent coronary heart disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do not think that taking hormones like estrogen helps prevent coronary heart disease. They do not recommend that women who have gone through menopause (stopped having periods) take estrogen to prevent coronary heart disease. But doctors sometimes prescribe estrogen for a short period of time to help with menopause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2050813\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=see_link\">",
"       Patient information: Pleuritic chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       Patient information: Nuclear heart testing (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       Patient information: Diet and health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/54/7012?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85797 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7012=[""].join("\n");
var outline_f6_54_7012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050649\">",
"      What is coronary heart disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050681\">",
"      Does coronary heart disease happen in women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050696\">",
"      What are the symptoms of coronary heart disease in women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050745\">",
"      Is there a test for coronary heart disease in women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050783\">",
"      Is there anything I can do to help prevent coronary heart disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050798\">",
"      Can taking hormones help prevent coronary heart disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2050813\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8356\">",
"      Coronary heart disease",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3331\">",
"       Heart attack",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/58/37797\">",
"        Heart attack symptoms",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38004\">",
"         Coronary artery bypass graft surgery",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=related_link\">",
"      Patient information: Pleuritic chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_54_7013="Fibrous pleural tumor I PA";
var content_f6_54_7013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrous tumor of the pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest frontal radiograph shows a mass at the left base replacing the left lateral costophrenic sulcus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7013=[""].join("\n");
var outline_f6_54_7013=null;
var title_f6_54_7014="Tetanus-diphtheria toxoid vaccination in adults";
var content_f6_54_7014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tetanus-diphtheria toxoid vaccination in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7014/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7014/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7014/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7014/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7014/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/54/7014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine is routinely recommended in children, with a single booster dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) recommended for 11 to 12-year-olds, followed by tetanus toxoid and the reduced diphtheria toxoid in the form of Td recommended at 10-year intervals throughout life (",
"    <a class=\"graphic graphic_figure graphicRef82617 graphicRef58209 \" href=\"UTD.htm?4/7/4218\">",
"     figure 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H19#H19\">",
"     \"Standard immunizations for children and adolescents\", section on 'Diphtheria, tetanus, and/or pertussis vaccines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these recommendations, immunity to tetanus and diphtheria continues to wane among adults in the United States. The magnitude of this effect was illustrated in a cross-sectional survey of individuals in the United States who were examined between 1988 and 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/1\">",
"     1",
"    </a>",
"    ]. Only 47 percent of adults over the age of 20 had protective antibody to both diseases and only 63 percent of adults with immunity to tetanus also had protective antibody to diphtheria. In comparison, 91 percent of children from 6 to 11 years of age had protective antibody to both diseases. Immunity to pertussis also wanes among adolescents and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale and risk-benefit considerations for the administration of tetanus-diphtheria toxoid (Td) vaccination in adults will be reviewed here. The use of the booster vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), immunizations in pregnant women, and the general principles behind adult immunization are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882660#H12882660\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of tetanus and diphtheria is discussed in detail elsewhere, but will be briefly reviewed here. Both infections are completely preventable with safe and effective toxoid vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of near universal vaccination of children with tetanus toxoid, the incidence of tetanus in the United States and the rest of the developed world has dropped dramatically and steadily since 1940. During the period between 2001 and 2008, the US Centers for Disease Control and Prevention (CDC) reported that there were 233 cases of tetanus in the United States, with an annual incidence of 0.10",
"    <span class=\"nowrap\">",
"     cases/million",
"    </span>",
"    population overall, and 0.23",
"    <span class=\"nowrap\">",
"     cases/million",
"    </span>",
"    among individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/2\">",
"     2",
"    </a>",
"    ] Unpredictable acute injuries remain the major cause of tetanus in the United States.",
"   </p>",
"   <p>",
"    Despite the low rate of clinical disease, many adults are inadequately vaccinated against tetanus. In the serologic survey cited above in the United States between 1988 and 1994, fully protective levels of antitetanus antibody were present in 72 percent of individuals &ge;6 years of age and only 31 percent of adults over the age of 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/1\">",
"     1",
"    </a>",
"    ]. Not surprisingly, protective antibody levels are more likely in adults with a history of military service, higher levels of education, higher incomes, and medical insurance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults age 65 years and older are at highest risk for both tetanus and tetanus-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/2\">",
"     2",
"    </a>",
"    ]. This is consistent with the decreasing proportion with age of persons who have received tetanus toxoid in the previous ten years among adults in the United States between 1993 and 1997: 65 percent between the ages of 18 and 49, 54 percent between the ages of 50 and 64, and 40 percent &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these observations in developed nations, approximately 1,000,000 cases of tetanus are estimated to occur in developing nations each year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link&amp;anchor=H2#H2\">",
"     \"Tetanus\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diphtheria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 60 percent of adults become susceptible to diphtheria because of waning vaccine-induced immunity and failure to receive recommended booster immunization. This was illustrated in the serologic survey cited above in the United States between 1988 and 1994: fully protective levels of antidiphtheria antibody were present in 61 percent of individuals &ge;6 years of age and only 30 percent of adults over the age of 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar findings were noted in 1995 study of 1000 United Kingdom-born blood donors in North London: 38 percent were susceptible to diphtheria (serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    concentration below 0.01",
"    <span class=\"nowrap\">",
"     IU/mL);",
"    </span>",
"    31 percent had basic protection; and 31 percent were fully protected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the frequent lack of immunity, there is still a low rate of clinical disease because immunization of the population has minimized the transmission of toxigenic strains. Only 45 cases of respiratory diphtheria were reported to the CDC from 1980 to 1996 (zero to five cases in any given year) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/6\">",
"     6",
"    </a>",
"    ]. However, unvaccinated or inadequately vaccinated travelers to endemic areas are at risk for acquiring this infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For reasons that are not well understood, pockets of diphtheria are reappearing, primarily in developing countries. The epidemics have involved nonimmunized or poorly immunized adults in addition to children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TD OR TDAP VACCINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Routine immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the serologic survey of individuals examined in the United States between 1988 and 1994, only 47 percent of adults over the age of 20 had protective antibody to both diseases and only 63 percent of adults with immunity to tetanus also had protective antibody to diphtheria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Waning immunity against tetanus and diphtheria is responsible for the recommendation for universal administration of Td boosters every 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/7\">",
"     7",
"    </a>",
"    ]. The United States Advisory Committee on Immunization Practices (ACIP) also recommends a single dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap; Adacel or Boostrix) 0.5 mL IM in place of Td for",
"    <strong>",
"     all",
"    </strong>",
"    adults aged 19 years and older who have not received Tdap previously to address waning immunity against pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Boostrix has been approved by the US Food and Drug Administration for individuals 10 years of age and older, whereas Adacel has only been approved for individuals between the ages of 11 and 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/9\">",
"     9",
"    </a>",
"    ]. In adults aged 65 years and older, Boostrix should be used when possible. If only Adacel is available, it may be used in this age group, since it has been shown to be immunogenic.",
"   </p>",
"   <p>",
"    When indicated, Tdap should be administered regardless of the interval since the last dose of Td [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This represents a change from previous ACIP guidelines, which recommended that Tdap be given a minimum of two years after the last dose of Td in most cases. The following Figures summarize the ACIP recommendations for immunization of adults without and with comorbidities, respectively (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. The use of Tdap is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882667#H12882667\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent tetanus doses, in the form of Td, should be given at 10-year intervals throughout adulthood.",
"   </p>",
"   <p>",
"    The use of Td and Tdap in pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunization for patients with injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of prior tetanus and diphtheria immunization, Td immunization should be reviewed when anyone presents with an acute injury or wound (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most patients who develop tetanus are not completely vaccinated and do not receive adequate wound prophylaxis, even when they present for medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/2\">",
"     2",
"    </a>",
"    ]. Incomplete vaccination is more likely in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Injection drug users",
"     </li>",
"     <li>",
"      Immigrants",
"     </li>",
"     <li>",
"      Rural populations",
"     </li>",
"     <li>",
"      Elderly adults",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adults presenting with wounds should have their tetanus immunization status reviewed and prophylaxis administered as indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to tetanus immunization, human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     tetanus immune globulin",
"    </a>",
"    is indicated in individuals who have sustained a wound that is more severe than a clean and minor wound (eg, wounds contaminated with dirt, feces, soil, or saliva; puncture wounds; avulsions; wounds resulting from missiles, crushing, burns, or frostbite)",
"    <strong>",
"     and",
"    </strong>",
"    who have either received fewer than three doses of tetanus toxoid previously or in whom the number of previous doses is unknown.",
"   </p>",
"   <p>",
"    If there is any doubt about whether or not an adult received the primary series, three doses of Td should be administered; the first dose and second dose should be separated by four weeks and the third dose should be given 6 to 12 months later (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 3",
"    </a>",
"    ). Appropriate tetanus prophylaxis should be administered as soon as possible following a wound, but should be given even to patients who present late for medical attention. This is because the incubation period is quite variable; most cases occur within eight days, but the incubation period can be as short as one day or as long as several months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link&amp;anchor=H9#H9\">",
"     \"Tetanus\", section on 'Incubation period'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since inadequate protection against diphtheria and tetanus often occur together [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7014/abstract/1\">",
"     1",
"    </a>",
"    ], Td is the preferred vaccine, not tetanus toxoid alone. The tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine should be used in place of Td in adults who have an indication (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Routine immunization'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882660#H12882660\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of ensuring that pregnant women have completed their primary series is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe systemic reactions, such as anaphylaxis, generalized urticaria, angioedema, and neurologic complications, have been reported following Td administration, but a causal relationship between the neurologic complications and vaccine administration have not been established. Patients who develop an arthus-like reaction tend to have high serum antitoxin levels and should be instructed to avoid booster doses more often than every 10 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2855909\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications and precautions are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef82075 \" href=\"UTD.htm?29/20/30030\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=see_link\">",
"       \"Patient information: Tetanus (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/61/33746?source=see_link\">",
"       \"Patient information: Tdap vaccine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28368389\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine is routinely recommended in children, with a single booster dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) recommended for 11 to 12-year-olds, followed by tetanus toxoid and the reduced diphtheria toxoid in the form of Td recommended at 10-year intervals throughout life (",
"      <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"       figure 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58209 \" href=\"UTD.htm?26/56/27523\">",
"       figure 1B",
"      </a>",
"      ). Despite these recommendations, immunity to tetanus and diphtheria continues to wane among adults in the United States. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The US Advisory Committee on Immunization Practices (ACIP) recommends a single dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) 0.5 mL IM in place of Td for",
"      <strong>",
"       all",
"      </strong>",
"      adults aged 19 years and older who have not received Tdap previously to address waning immunity against pertussis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Routine immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of prior tetanus and diphtheria immunization, Td immunization should be reviewed when anyone presents with an acute injury or wound and prophylaxis administered as indicated (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ). In addition to tetanus immunization, human",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"       tetanus immune globulin",
"      </a>",
"      is indicated in individuals who have sustained a wound that is more severe than a clean and minor wound (eg, wounds contaminated with dirt, feces, soil, or saliva; puncture wounds; avulsions; wounds resulting from missiles, crushing, burns, or frostbite) AND who have either received fewer than three doses of tetanus toxoid previously or in whom the number of previous doses is unknown. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunization for patients with injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is any doubt about whether or not an adult received the primary series, three doses of Td should be administered; the first dose and second dose should be separated by four weeks and the third dose should be given 6 to 12 months later. The tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine should be used in place of Td in adults who have an indication (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunization for patients with injuries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/1\">",
"      McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Tetanus surveillance --- United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011; 60:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/3\">",
"      Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332:761.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Influenza, pneumococcal and tetanus toxoid vaccination of adults &mdash; United States, 1993-1997. MMWR Morb Mortal Wkly Rep 2000; 49(SS-9):39. file://www.cdc.gov/mmwr/preview/mmwrhtml/ss4909a3.htm (Accessed on June 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/5\">",
"      Maple PA, Efstratiou A, George RC, et al. Diphtheria immunity in UK blood donors. Lancet 1995; 345:963.",
"     </a>",
"    </li>",
"    <li>",
"     CDC www.cdc.gov/nip/ (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/7\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/10\">",
"      Brauner JS, Vieira SR, Bleck TP. Changes in severe accidental tetanus mortality in the ICU during two decades in Brazil. Intensive Care Med 2002; 28:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7014/abstract/11\">",
"      Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry 2000; 69:292.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Tetanus (lockjaw). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, American Academy of Pediatrics, Elk Grove Village, IL 2012. p.707.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3897 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7014=[""].join("\n");
var outline_f6_54_7014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28368389\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDICATIONS FOR TD OR TDAP VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Routine immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunization for patients with injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2855909\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28368389\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3897|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/55/25463\" title=\"figure 1A\">",
"      Childhood immunization schedule 0 to 6 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27523\" title=\"figure 1B\">",
"      Childhood immunization schedule 7 to 18 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37701\" title=\"figure 2\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 3\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3897|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/20/30030\" title=\"table 2\">",
"      Contraindications and precautions adult vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/61/33746?source=related_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=related_link\">",
"      Patient information: Tetanus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_54_7015="Rheumatic and bone disorders associated with acromegaly";
var content_f6_54_7015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rheumatic and bone disorders associated with acromegaly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Lesley D Hordon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7015/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/54/7015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly is a rare disorder characterized by excess secretion of growth hormone (GH) and its principle mediator, insulin-like growth factor (IGF)-1. Rheumatic problems are frequently seen in acromegaly including an arthropathy, which can be severe and disabling; carpal tunnel syndrome, which is often reversible; and a peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/1\">",
"     1",
"    </a>",
"    ]. These findings may, in some cases, be a prominent initial sign of acromegaly. Acromegaly should be remembered as a rare but important cause of osteoarthritis, particularly if osteoarthritis is premature or is associated with carpal tunnel syndrome.",
"   </p>",
"   <p>",
"    The rheumatologic and bone disorders associated with acromegaly are reviewed here. The causes, other clinical manifestations, diagnosis, and treatment of acromegaly are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link\">",
"     \"Diagnosis of acromegaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link\">",
"     \"Treatment of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARTHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint and spine disorders, most likely due to acceleration of the normal growth process, are common in acromegaly and may dominate the clinical picture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone and IGF-1 are essential for normal growth, differentiation, and repair of cartilage and bone. Excess GH leads to a form of osteoarthritis. A mechanism has been proposed to explain this process based upon in vitro studies assessing the effects of GH and IGF-1 on cartilage and connective tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excess GH and IGF-1 cause proliferation of articular chondrocytes and increased matrix production. This leads to thickened articular cartilage and widening of the joint spaces.",
"     </li>",
"     <li>",
"      GH also affects connective tissue, promoting the growth of periarticular structures which results in ligamentous laxity and joint instability. Synovial hypertrophy also occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These processes eventually lead to wear and fissuring of the cartilage. Abnormalities in repair mechanisms, probably also due to excess GH, result in overproliferation of regenerating fibrocartilage, which may then become calcified and result in osteophyte formation. Accelerated turnover of underlying bone, subchondral cyst formation, eventual thinning of articular cartilage, and a reduction in joint space complete the picture of an osteoarthritis.",
"   </p>",
"   <p>",
"    A study of 67 acromegalic patients in long-term remission found an association between the pretreatment IGF-1 SD scores and the risk of osteoarthritis of hip, hands, and cervical spine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies noted joint symptoms in the majority of patients with acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the prevalence of joint disease in some of the later series has been lower, probably due to earlier recognition and to improved therapy. In a report of 500 patients in 1994, for example, osteoarthritis was noted in approximately 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/4\">",
"     4",
"    </a>",
"    ]. A smaller series of 151 patients followed for 12 years found severe arthritis in 18 percent of the 119 survivors and mild arthritis in 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/5\">",
"     5",
"    </a>",
"    ]. However, a detailed study of 89 patients with adequate long-term control of acromegaly showed radiographic evidence of osteoarthritis at one or more joint sites in 99 percent of patients and symptoms of pain and stiffness at one site or more in 72 percent of patients overall [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/6\">",
"     6",
"    </a>",
"    ]. Osteoarthritis was significantly more common and occurred at a younger age than in the control group.",
"   </p>",
"   <p>",
"    Comparison of studies is difficult as differences reflect the different diagnostic criteria used for osteoarthritis, the age and sex distribution of the population studied, and the degree of control and duration of acromegaly. The prevalence of radiographic osteoarthritis may be higher than symptomatic osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main manifestations of the arthropathy in acromegaly include joint pain, particularly on activity. Joint swelling and tightness, crepitus, and effusions have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/5,7-9\">",
"     5,7-9",
"    </a>",
"    ]. Hyperlaxity of the joints and spine can also occur, often followed by stiffness due to a combination of degenerative changes and thickening of subcutaneous tissues. Spinal pain is common, occurring in one-half of patients, and kyphoscoliosis is seen in up to 20 percent.",
"   </p>",
"   <p>",
"    The sites of involvement, peripherally and axially, are variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peripheral joints most commonly affected are the knee and shoulder, while involvement of the elbow and hand is less common.",
"     </li>",
"     <li>",
"      Among those with axial involvement, the lumbosacral spine is affected in one-half of patients; one-third of patients also have involvement of the cervical or thoracic spine. Features of diffuse idiopathic skeletal hyperostosis (DISH) may be seen in 20 percent, correlating with impaired glucose tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=see_link\">",
"       \"Diffuse idiopathic skeletal hyperostosis (DISH)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Temporomandibular pain and malocclusion were reported in one-third of patients in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The acromegalic rosary is a palpable but not necessarily visible enlargement of the costochondral junctions. This finding occurred in 26 out of 27 subjects in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between the severity of joint involvement and the severity and duration of acromegaly is debatable. Arthropathy appears to be more common in older patients with a longer duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. However, there is wide variability, and arthropathy is the presenting complaint in some patients. The presence of osteoarthritis is not significantly associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/12\">",
"     12",
"    </a>",
"    ] but has a significant negative impact on quality of life. A study of 118 acromegalic patients in remission showed that 77 percent had self-reported joint problems, particularly of the hip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    knee [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/13\">",
"     13",
"    </a>",
"    ]. A study of 58 patients with acromegaly of over five years' duration showed that 90 percent reported musculoskeletal pain associated with reduced quality of life and poor sleep, with 88 percent consulting their general practitioner for pain and with over half consulting complementary medicine therapists [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic changes of the arthropathy in acromegaly are not necessarily associated with clinical symptoms and vary according to the stage of the arthropathy. Widening of joint spaces due to cartilage overgrowth and thickening of the soft tissues occurs in the early stages (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64058 \" href=\"UTD.htm?26/42/27311\">",
"     image 1",
"    </a>",
"    ), progressing to cartilage loss and the radiographic features of degenerative joint disease, which are eventually indistinguishable from osteoarthritis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82074 \" href=\"UTD.htm?15/31/15856\">",
"     image 2",
"    </a>",
"    ). There can be persistence of the characteristic radiographic findings of wide joint spaces, despite long-term control of acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/6\">",
"     6",
"    </a>",
"    ]; these changes may be associated with more self-reported pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/15\">",
"     15",
"    </a>",
"    ]. Joint radiographs of the arthritis of acromegaly exhibit more osteophyte formation and less joint space narrowing at the hip and knee, compared with those of patients with primary generalized osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition to these changes in the joints, thickening of the heel pad is often seen.",
"   </p>",
"   <p>",
"    Chondrocalcinosis has also been reported in association with acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/17\">",
"     17",
"    </a>",
"    ]. It is not clear, however, if this is a real or coincidental finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of the arthropathy and much of the cartilaginous thickening may improve with treatment of the acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. A decrease toward normal of articular cartilage thickness has been documented ultrasonographically following 12 months of treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/19\">",
"     19",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link\">",
"     \"Treatment of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, once bone damage has occurred, the arthritis is irreversible and tends to progress despite adequate control of GH secretion. In this setting, standard measures for the treatment of any degenerative arthropathy apply, including medications for pain relief, physiotherapy, occupational therapy, and, if necessary, joint replacement. Intraarticular glucocorticoid injection appears to be ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/9\">",
"     9",
"    </a>",
"    ]. It is important to assess routinely for musculoskeletal problems in acromegaly and to provide appropriate multidisciplinary treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARPAL TUNNEL SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome is common in acromegaly. Up to one-third of patients have median nerve compression, which is frequently bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/4\">",
"     4",
"    </a>",
"    ]. These findings are due to soft tissue enlargement (synovial edema and tendon hyperplasia). Correction of the acromegaly usually leads to rapid resolution of symptoms, unlike established arthropathy, although 18 percent of patients in one series required surgery for carpal tunnel syndrome during the course of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/13\">",
"     13",
"    </a>",
"    ]. However, in a series of 58 patients with longstanding acromegaly, in which musculoskeletal symptoms were specifically addressed, 17 percent were found to have had previous carpal tunnel decompression, and 40 percent had had symptoms of carpal tunnel at diagnosis. Symptoms were present at the time of the study in 31 percent, with 20 percent showing evidence of median nerve compression by Tinel&rsquo;s or Phalen&rsquo;s test. The authors of the study suggested that carpal tunnel syndrome may be a longer-term problem requiring further treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PERIPHERAL NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy occurs in approximately one-half of acromegalic patients and may contribute to muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/4\">",
"     4",
"    </a>",
"    ]. The nerve damage may be due to the acromegaly itself and to concurrent diabetes mellitus, which develops in 30 percent of cases. The component due to acromegaly appears to involve segmental demyelination without evidence of axonal degeneration; there is eventual irreversible hypertrophy of the Schwann cell system of the small diameter fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/21\">",
"     21",
"    </a>",
"    ]. Peripheral nerve enlargement (median, ulnar) can be detected by ultrasound and appears to be related to disease control, to IGF-1 levels, and to duration of acromegaly. The enlargement of the nerves is not confined to potential entrapment areas (cubital, carpal tunnel) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/22\">",
"     22",
"    </a>",
"    ]. While nerve cross-sectional area decreases with successful treatment over a one-year follow-up period, nerves still remain larger than controls. Reduction in nerve enlargement is proportional to the degree of disease control, particularly levels of IGF-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BONE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH is involved in the regulation of bone turnover and remodeling, probably both directly and indirectly via the production of IGF-I [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Excess GH secretion results in increased bone turnover as demonstrated histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/26\">",
"     26",
"    </a>",
"    ] and by studies using biochemical markers of bone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/27\">",
"     27",
"    </a>",
"    ]. It has been suggested that the action of GH on bone turnover in acromegaly may be mediated via parathyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although acromegaly was previously thought to be associated with vertebral fractures and was considered a cause of osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/29\">",
"     29",
"    </a>",
"    ], subsequent studies have found inconsistent results concerning the relationship between acromegaly and bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/26,27,30-32\">",
"     26,27,30-32",
"    </a>",
"    ]. These differences may relate to the sites at which bone mineral density (BMD) was measured, to the duration and activity of acromegaly, or to the presence of hypogonadism; the last factor may be the most important. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among eugonadal patients, forearm and hip BMDs are preserved or are even enhanced, and they may be higher than those among hypogonadal acromegalic patients or control subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/30,32-36\">",
"       30,32-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypogonadal patients with acromegaly have a lower BMD as measured in the spine than eugonadal patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/31,36\">",
"       31,36",
"      </a>",
"      ]; vertebral BMD appears to depend more upon gonadal status than acromegalic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/30,36\">",
"       30,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The majority of patients with acromegaly have a lumbar BMD similar to that of controls, although some hypogonadal patients may be osteopenic [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/30-34,37,38\">",
"       30-34,37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pituitary irradiation may be a strong negative predictor of bone mass. This has been hypothesized to be due to reduced growth hormone secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although changes in BMD and bone turnover in acromegaly have been extensively studied, there are few clinical data concerning the prevalence of peripheral or vertebral fracture, and published studies report disparate results. The following are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 206 surgically treated patients, fracture risk appeared to be reduced prior to diagnosis, and a trend was still seen toward a decrease in fracture risk after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, a small cross-sectional study of 36 postmenopausal women with acromegaly showed 19 (53 percent) to have radiological vertebral fractures, with a significantly higher fracture rate in those with active compared with controlled disease, although fractures tended to be less severe in the active group [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/40\">",
"       40",
"      </a>",
"      ]. Only 25 percent of those with vertebral fracture and active acromegaly were osteoporotic (T score &lt;-2.5) compared with 57 percent of those with controlled acromegaly and vertebral fracture.",
"     </li>",
"     <li>",
"      A study of 40 acromegalic men showed a significantly greater prevalence of vertebral fractures than controls, who were matched for age and gonadal status (57.5 versus 22.6 percent). Bone mineral density was not significantly different between acromegalic patients and controls. Acromegalic patients with fractures had significantly higher IGF-1 values and a longer duration of active disease than acromegalic patients without fractures, as well as longer duration of untreated hypogonadism. The duration of active acromegaly was the only risk factor significantly correlated with fracture occurrence in a multivariate logistic regression analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 89 patients (46 percent male) with controlled acromegaly showed a high prevalence of vertebral fractures (59 percent) with a mean number of 3.4 fractures per person in those who had fractured. Fractures were more common in men (64 percent), and there was no relationship between the presence or absence of fractures and BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible explanations have been offered for both reduced and increased fracture rates in active disease. The former has been ascribed to the anabolic effects of excess growth hormone on bone mineral [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/39\">",
"     39",
"    </a>",
"    ], and the latter has been postulated to be due to impaired bone quality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7015/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4420542\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Joint and spine disorders, including osteoarthritis, are common in acromegaly and may dominate the clinical picture; these effects appear to be due to acceleration of the normal growth process by excess growth hormone (GH) and insulin-like growth factor-1, which are essential for normal growth, differentiation, and repair of cartilage and bone. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Arthropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main manifestations of the arthropathy in acromegaly include joint pain, particularly on activity. Joint swelling and tightness, crepitus, effusions, and hyperlaxity of the joints and spine may occur. Spinal pain is common, and kyphoscoliosis may be seen. The peripheral joints most commonly affected are the knee and shoulder. Axial involvement may affect any portion of the spine but is most common in the lumbar region, and features of diffuse idiopathic skeletal hyperostosis (DISH) may be present. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiographic changes of the arthropathy in acromegaly vary according to the stage of the arthropathy. Widening of joint spaces due to cartilage overgrowth and thickening of the soft tissues occurs in the early stages (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64058 \" href=\"UTD.htm?26/42/27311\">",
"       image 1",
"      </a>",
"      ), progressing to osteophyte formation, cartilage loss, and degenerative joint disease, which is eventually indistinguishable from osteoarthritis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82074 \" href=\"UTD.htm?15/31/15856\">",
"       image 2",
"      </a>",
"      ). In addition, thickening of the heel pad is often seen. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of the arthropathy and much of the cartilaginous thickening may improve with treatment of the acromegaly. In many patients, however, symptoms persist, and, once bone damage has occurred, the arthritis is irreversible and tends to progress despite adequate control of GH secretion. In this setting, standard measures for the treatment of any degenerative arthropathy apply. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carpal tunnel syndrome is common in acromegaly, in which it is due to soft tissue enlargement (synovial edema and tendon hyperplasia). Correction of the acromegaly usually leads to rapid resolution of symptoms, unlike established arthropathy, although symptoms can be sustained. Additional intervention may be required. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Carpal tunnel syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral neuropathy can occur and may contribute to muscle weakness. The nerve damage may be due to the acromegaly itself and to concurrent diabetes mellitus. Peripheral nerve enlargement can be detected by ultrasound and appears to be related to disease control, to IGF-1 levels, and to duration of acromegaly. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Peripheral neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effects of acromegaly on bone mineral density and fracture risk are uncertain, and study results are inconsistent. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bone disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The arthropathy of acromegaly has a significant impact on quality of life. It is important to assess routinely for musculoskeletal problems and to provide appropriate multidisciplinary treatment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/1\">",
"      Lieberman SA, Bj&ouml;rkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992; 21:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/2\">",
"      Biermasz NR, Wassenaar MJ, van der Klaauw AA, et al. Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. J Clin Endocrinol Metab 2009; 94:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/3\">",
"      KELLGREN JH, BALL J, TUTTON GK. The articular and other limb changes in acromegaly; a clinical and pathological study of 25 cases. Q J Med 1952; 21:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/4\">",
"      Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/5\">",
"      Layton MW, Fudman EJ, Barkan A, et al. Acromegalic arthropathy. Characteristics and response to therapy. Arthritis Rheum 1988; 31:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/6\">",
"      Wassenaar MJ, Biermasz NR, van Duinen N, et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. Eur J Endocrinol 2009; 160:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/7\">",
"      Dons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf) 1988; 28:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/8\">",
"      Podgorski M, Robinson B, Weissberger A, et al. Articular manifestations of acromegaly. Aust N Z J Med 1988; 18:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/9\">",
"      Detenbeck LC, Tressler HA, O'Duffy JD, Randall RV. Peripheral joint manifestations of acromegaly. Clin Orthop Relat Res 1973; :119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/10\">",
"      Scarpa R, De Brasi D, Pivonello R, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab 2004; 89:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/11\">",
"      Ibbertson HK, Manning PJ, Holdaway IM, et al. The acromegalic rosary. Lancet 1991; 337:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/12\">",
"      Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/13\">",
"      Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/14\">",
"      Miller A, Doll H, David J, Wass J. Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 2008; 158:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/15\">",
"      Biermasz NR, van 't Klooster R, Wassenaar MJ, et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol 2012; 166:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/16\">",
"      Wassenaar MJ, Biermasz NR, Bijsterbosch J, et al. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 2011; 70:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/17\">",
"      Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/18\">",
"      Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998; 83:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/19\">",
"      Colao A, Cannav&ograve; S, Marzullo P, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol 2003; 148:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/20\">",
"      Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) 1999; 51:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/21\">",
"      Dinn JJ, Dinn EI. Natural history of acromegalic peripheral neuropathy. Q J Med 1985; 57:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/22\">",
"      Tagliafico A, Resmini E, Nizzo R, et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. J Clin Endocrinol Metab 2008; 93:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/23\">",
"      Resmini E, Tagliafico A, Nizzo R, et al. Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up. Clin Endocrinol (Oxf) 2009; 71:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/24\">",
"      Inzucchi SE, Robbins RJ. Growth hormone and the maintenance of adult bone mineral density. Clin Endocrinol (Oxf) 1996; 45:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/25\">",
"      Ohlsson C, Bengtsson BA, Isaksson OG, et al. Growth hormone and bone. Endocr Rev 1998; 19:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/26\">",
"      Halse J, Melsen F, Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol (Copenh) 1981; 97:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/27\">",
"      Ezzat S, Melmed S, Endres D, et al. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993; 76:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/28\">",
"      White HD, Ahmad AM, Durham BH, et al. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 2006; 91:913.",
"     </a>",
"    </li>",
"    <li>",
"     Albright F, Reifenstein EC. The parathyroid glands and metabolic bone disease: Selected studies, Williams and Wilkins, Philadelphia 1948. p.188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/30\">",
"      Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 1989; 111:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/31\">",
"      Ho PJ, Fig LM, Barkan AL, Shapiro B. Bone mineral density of the axial skeleton in acromegaly. J Nucl Med 1992; 33:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/32\">",
"      Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 1997; 7:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/33\">",
"      Kotzmann H, Bernecker P, H&uuml;bsch P, et al. Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 1993; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/34\">",
"      Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 1997; 12:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/35\">",
"      Jockenh&ouml;vel F, Rohrbach S, Deggerich S, et al. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1996; 1:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/36\">",
"      Lesse GP, Fraser WD, Farquharson R, et al. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf) 1998; 48:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/37\">",
"      Biermasz NR, Hamdy NA, Pereira AM, et al. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur J Endocrinol 2005; 152:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/38\">",
"      Battista C, Chiodini I, Muscarella S, et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol (Oxf) 2009; 70:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/39\">",
"      Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone. Osteoporos Int 2004; 15:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/40\">",
"      Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005; 20:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/41\">",
"      Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008; 93:4649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7015/abstract/42\">",
"      Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 2011; 164:475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5617 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7015=[""].join("\n");
var outline_f6_54_7015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4420542\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARTHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARPAL TUNNEL SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PERIPHERAL NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BONE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4420542\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5617|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/42/27311\" title=\"diagnostic image 1\">",
"      Early acromegalic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/31/15856\" title=\"diagnostic image 2\">",
"      Late acromegalic arthropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=related_link\">",
"      Diffuse idiopathic skeletal hyperostosis (DISH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=related_link\">",
"      Treatment of acromegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_54_7016="Cherney incision";
var content_f6_54_7016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Cherney incision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 620px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Transverse incision of rectus sheath. (B) Lower sheath is separated from rectus muscles. Tendons are exposed and incised 0.5 cm above periosteum of symphysis. (C) Tendons are sutured to lower rectus sheath above symphysis with permanent suture material. (D) Sheath is closed in a continuous manner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7016=[""].join("\n");
var outline_f6_54_7016=null;
var title_f6_54_7017="Biology and genetics of prions";
var content_f6_54_7017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology and genetics of prions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Henry G Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7017/contributors\">",
"     John M Lee, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7017/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/54/7017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably once clinical symptoms appear. Five human prion diseases are currently recognized: kuru, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD also known as new variant CJD), Gerstmann-Str&auml;ussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Bovine spongiform encephalopathy (BSE), one of a number of prion infections affecting animals, has helped to focus more widespread public attention on these diseases with its possible link to vCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These human prion diseases share certain common neuropathologic features including neuronal loss, proliferation of glial cells, absence of an inflammatory response, and the presence of small vacuoles within the neuropil which produces a spongiform appearance. Current evidence indicates that prion diseases are associated with the accumulation of an abnormal form of a host cell protein, designated the prion protein (PrP) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biology of prions will be reviewed here. The clinical manifestations, genetics, and diagnosis of prion diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link\">",
"     \"Diseases of the central nervous system caused by prions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY OF PRIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. Stanley Prusiner coined the term \"prion\" in 1982 which he defined as a small infectious pathogen containing protein but apparently lacking nucleic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/8\">",
"     8",
"    </a>",
"    ]. The prion protein (PrP) is the critical component of these agents and may, in fact, be its exclusive constituent.",
"   </p>",
"   <p>",
"    One of the characteristic features of prions is their resistance to a number of normal decontaminating procedures. These pathogens are resistant to processes affecting nucleic acids, such as hydrolysis or shearing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/9\">",
"     9",
"    </a>",
"    ]. However, agents that digest, denature or modify proteins do have activity against prions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/7\">",
"     7",
"    </a>",
"    ]. The prion protein purified from the brains of scrapie-infected animals (PrPSc) can be inactivated by prolonged autoclaving (at 121&ordm;C and 15 psi for 4.5 h), or immersion in 1N NaOH (for 30 min, repeat three times), or in concentrated (&gt;3 M) solutions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     guanidine",
"    </a>",
"    thiocyanate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/10\">",
"     10",
"    </a>",
"    ]. However, certain cautions prevail; it appears that inadequate autoclaving can establish heat resistant subpopulations which fail to diminish with a further cycle of autoclaving [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/11\">",
"     11",
"    </a>",
"    ]. Stainless steel instruments also may retain infectivity even after treatment with 10 percent formaldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer decontamination techniques are being investigated. There has been some success in sterilization using a combination of SDS, proteinase K and pronase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/14\">",
"     14",
"    </a>",
"    ]. A radio-frequency gas-plasma treatment has been shown to effectively decontaminate surgical instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/15\">",
"     15",
"    </a>",
"    ]. Another group has tested a decontamination formula combining copper metal ions with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prion protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrapie prions have been used as a model for prion diseases. PrPSc is a conformational isomer of PrPC, a membrane-bound glycophosphatidylinositol-anchored protein found in the brains of normal animals on both neuronal and non-neuronal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Similar proteins are also found in yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal function of PrPC is unknown. &nbsp;A number of studies have shown that the prion protein is capable of reversibly binding to copper ions, suggesting that the prion protein could play a role in copper homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. Copper, itself, plays a role in endocytosis and neurotransmission. Furthermore, PrPC acts as a mediator of copper superoxide dismutase involved in the cellular response to oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and it may play a role in regulating apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/23\">",
"     23",
"    </a>",
"    ]. PrPC is also expressed throughout the cells of the immune system, red blood cells, and platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/24\">",
"     24",
"    </a>",
"    ]. One study found that prion protein was upregulated during T cell activation and that antibody cross-linking of surface PrP led to increased phosphorylation of signaling proteins, suggesting a role for PrPC in immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PrPC exists primarily in an alpha helical conformation, while PrPSc is beta helical and appears to result from a yet uncharacterized conformational alteration in PrPC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Recombinant forms of prion protein show a large unstructured protein motif, which may more easily convert to a beta structure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The PrPSc molecules form amyloid fibrils, which show apple-green birefringence upon polarization after Congo red staining. The fibrils are made of a continuous array of beta sheets that are oriented perpendicular to the fibril axis. The resistance of PrPSc to digestion with proteases and its tendency to polymerize into scrapie-associated fibrils or prion rods differentiates PrPSc from PrPC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The hydrophobicity of this protein, which may in turn affect aggregation, and its beta-sheet conformation may play a role in neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Biosynthesis of PrPC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key step during the biosynthesis of PrPC involves modification of both the amino and carboxy terminals with the addition of a phosphatidylinositol glycolipid which serves to anchor the protein to the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]. PrPC can be detected attached to the plasma membrane of neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/35\">",
"     35",
"    </a>",
"    ] and may be concentrated at synaptic membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, PrPC also has transmembrane domains, indicating that it spans the cellular cytoplasmic membrane. Surface PrPC is degraded after endocytosis in acidic vesicles, although some protein may recycle to the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/37\">",
"     37",
"    </a>",
"    ]. Secreted forms of PrPC also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies have shown the importance of glycosylation in the formation of PrPSc. Changes in electrophoretic mobility are linked to different phenotypic presentations of CJD. These changes are due to both variation in amino acid sequence as well as glycosylation of the prion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Furthermore, infectivity across the species barrier is enhanced when unglycosylated forms of the prion protein are used, and conversion of PrPC to PrPSc is inhibited by glycosylation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Conversion of PrPC to PrPSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to PrPC, PrPSc accumulates within cells and does not normally appear on the cell surface. PrPSc is found predominantly in cytoplasmic vacuoles and secondary lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/42\">",
"     42",
"    </a>",
"    ]. Conversion of PrPC to PrPSc may occur in caveolae-like membranous domains [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in mice either devoid of PrPC or with abnormal isoforms indicate that host PrPC must be present for the development of prion disease. Prion diseases appear to result from accumulation of abnormal isoforms of the PrP which is dependent upon conversion of normal PrPC into PrPSc [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This conversion appears to be the result of a conformational change in PrPC, rather than a chemical modification.",
"   </p>",
"   <p>",
"    One group developed a peptide, iPrP13, that can break a beta-sheet conformation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/46\">",
"     46",
"    </a>",
"    ]. This peptide was able to reduce the protease resistance of PrPSc and to delay the onset of symptoms in transmission experiments in mice. It has been hypothesized that another as yet unidentified host factor, designated protein X, may facilitate conversion of normal PrP to PrPSc by binding to the carboxy terminus of PrPC and interacting with a site near the N-terminus of the protein to effect a conformational change [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study used transgenic mice with an abnormal form of PrPC lacking the glycophospholipid cell membrane anchor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/48\">",
"     48",
"    </a>",
"    ]. When inoculated with PrPSc, these mice accumulated abnormal PrP in abundant amyloid plaques but were asymptomatic and did not accumulate PrPSc or develop titers of infectivity at nearly the same rate as wild-type mice. The PrP membrane anchor appears necessary in the pathogenesis of prion disease. This study also emphasizes the specific neurotoxic role of PrPSc beyond amyloid deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How the first molecule of PrPSc appears in the host remains a mystery, but the initial appearance, which may be de novo, probably triggers the replication of PrPSc. This process has been compared to crystallization in solution where a single seed crystal serves as a nidus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/6\">",
"     6",
"    </a>",
"    ]. It is hypothesized that the initiating PrPSc molecule is derived from an exogenous source in sporadic and iatrogenic prion diseases, while mutations are invariably detected within the gene encoding PrP in familial forms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/50\">",
"     50",
"    </a>",
"    ]. These mutations could destabilize PrPC, which might lead to spontaneous conversion to PrPSc. Studies of yeast prion Sup53 have shown that small, specific, elements of the primary amino acid sequence are responsible for initial nucleation as well as for specific prion conformations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Possible role for immune response in early pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to transport to the nervous system, follicular dendritic cells within germinal centers of lymphoid tissue appear to act as a reservoir for the protein. Two reports suggest that complement plays a role in early pathogenesis. Mice deficient in C3 or C1q had decreased stores of PrPSc in the spleen and delayed onset of neurologic disease following peripheral inoculation in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/52\">",
"     52",
"    </a>",
"    ]. A companion report showed partial or full protection against spongiform encephalopathy in mice deficient in C3, C1q,",
"    <span class=\"nowrap\">",
"     Bf/C2,",
"    </span>",
"    or complement receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/53\">",
"     53",
"    </a>",
"    ]. Other studies have shown variable immune responses to different experimental conformations of the prion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transport of PrPSc to the nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transport of PrPSc to the nervous system, once it appears in the host, occurs via axons [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/55\">",
"     55",
"    </a>",
"    ]. Previous investigations suggested that the predominant mechanism was by slow axoplasmic transport [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/56\">",
"     56",
"    </a>",
"    ]. However, several studies provide data showing that rapid anterograde axonal transport also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In one of these reports, a specific isoform of the protein was transported via this route in a hamster model compared to several other isoforms found within neural tissues, which appeared to arrive by a slower transport mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of PrPC and PrPSc in olfactory sensory neurons has suggested that the olfactory system may serve as an entry pathway for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the lymphoreticular system appears to play the more critical role in the initiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    propagation of some prion diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Studies in mice indicate that for some prion diseases acquired by innoculation (including intranasal inoculation), a period of replication in lymphoreticular tissue is required [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. Other studies found PrPSc expressed in the spleens of mice that were inoculated with prion disease directly into the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/61\">",
"     61",
"    </a>",
"    ]. Splenectomized mice developed prion disease more slowly than nonsplenectomized mice after intracerebral inoculation. Involvement of the lymphoreticular system seems more likely for certain types of exogenously acquired prion diseases, such as iatrogenic CJD, kuru, and perhaps vCJD, than for sporadic and genetic forms of prion diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurotoxicity of prion protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;PrPSc appears to be neurotoxic; accumulation of this protein or fragments of it in neurons leads to apoptosis and cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. As an example, the PrP fragment containing amino acids 106-126 induces death of hippocampal neurons following exposure in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/63\">",
"     63",
"    </a>",
"    ]. PrPC must be present for this effect to occur; PrP106-126 does not destroy neurons in mice which do not express PrPC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/64\">",
"     64",
"    </a>",
"    ]. However, abnormal PrP released by astrocytes still destroys PrP negative neurons in mice, suggesting that the neuronal injury is not caused by a loss of function of normal neuronal PrP or any interaction between normal and abnormal forms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Misfolded PrP is transported in a retrograde fashion to the cytosol for degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/66\">",
"     66",
"    </a>",
"    ]. Even small amounts of this protein in the cytosol are highly neurotoxic, and this accumulation may be an important step in prion disease pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Demonstration of PrPSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry techniques such as ELISA have been used to detect the presence and levels of disease-causing PrPSc in human brain tissue at autopsy or in biopsy samples [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/68\">",
"     68",
"    </a>",
"    ]. These methods use limited proteolysis to hydrolyze the normal precursor cellular PrPC in order to measure the protease-resistant core of the pathologic PrPSc. Subsequently, the conformation-dependent immunoassay (CDI) method was developed that did not require proteolysis to digest PrPC, and it was discovered that PrPSc exists in both protease resistant and protease sensitive forms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/69\">",
"     69",
"    </a>",
"    ]. Thus, unlike other immunoassays, the CDI is able to measure both protease resistant and protease sensitive forms of PrPSc [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CDI appears to have a much higher sensitivity for the diagnosis of sCJD disease compared with routine neuropathologic examination and immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/70\">",
"     70",
"    </a>",
"    ]. While this method appears promising, further study is needed to determine its specificity as well as its role in other human prion diseases, particularly variant CJD, and its possible antemortem diagnostic utility in brain biopsy and extraneural tissue specimens.",
"   </p>",
"   <p>",
"    Another promising method is one that amplifies prion protein in blood by a process called protein misfolding cyclic amplification (PMCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/71\">",
"     71",
"    </a>",
"    ]. This technique may enable later detection with a variety of methods. A study by the same group of investigators showed that this method could detect a biphasic appearance of PrPSc in inoculated hamsters [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/72\">",
"     72",
"    </a>",
"    ]. PrPSc was detected in about one-half of asymptomatic animals three to six weeks postinoculation. The signal subsequently disappeared, and then reappeared four months postinnoculation when the hamsters became symptomatic. This method may become useful in assessing asymptomatic blood donors.",
"   </p>",
"   <p>",
"    Antibodies that uniquely react with PrPSc may provide a diagnostic method for prion disease. Investigators have described a repeat Tyr-Tyr-Arg epitope that is hidden in PrPC but becomes accessible in PrPSc following the misfolding process [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/73\">",
"     73",
"    </a>",
"    ]. Monoclonal and polyclonal antibodies raised to this moiety react with scrapie-infected mouse and hamster brain tissue and not with normal brain tissue, which raises the possibility that these antibodies might serve as diagnostic test reagents. Other methods are also in development [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/74-79\">",
"     74-79",
"    </a>",
"    ]. The need for a highly sensitive and specific test to detect PrPSc will increase when effective treatment for human prion disease becomes available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENETICS OF HUMAN PRION DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene encoding PrP (\"PRNP\") in humans is located on the short arm of chromosome 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/80\">",
"     80",
"    </a>",
"    ]. A strong link was established between mutations in the PRNP gene and forms of prion disease with a familial predisposition (fCJD, GSS, FFI). More than 50 different mutations have been identified, including point and premature STOP codon mutations as well as the insertion of octapeptide repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Some experts have advocated classifying prion diseases based upon the responsible mutation rather than the traditional classifications such as fCJD or GSS since a single mutation can produce different clinical phenotypes in different individuals or families (ie, genetic pleiotropy) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/80,83-85\">",
"     80,83-85",
"    </a>",
"    ]. As an example, the D178N mutation, in which asparagine substitutes for aspartic acid in codon 178, occurs in families with FFI, fCJD, and GSS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/80\">",
"     80",
"    </a>",
"    ]. Pedigrees with this mutation often demonstrate marked variability in the age of onset as well as the disease phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/84\">",
"     84",
"    </a>",
"    ]. A large English and Irish kindred has been described containing individuals diagnosed with a variety of conditions including CJD, vCJD, and GSS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/85\">",
"     85",
"    </a>",
"    ]. However, when the PRNP gene was examined, all affected individuals had a valine for alanine substitution at codon 117 regardless of the clinical diagnosis.",
"   </p>",
"   <p>",
"    Codon 129 of the PRNP gene is a polymorphic codon; normal individuals have either valine or methionine at that site [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. Neither V129 nor M129 appears to be pathogenic itself. However, genotype-phenotype correlation studies suggest that amino acid 129 allele status modifies the effect of other pathogenic PRNP mutations. The modifying influence appears to be a cis-acting effect, meaning that the impact on phenotype is due to the presence of both variants in the same protein product. The effect is likely a result of the joint effect of both variants together on conferring a unique conformational change in protein structure, resulting in altered patterns of PRNP cleavage by proteases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients with the D178N mutation who are homozygous for valine at codon 129 appear to develop CJD, while those who are homozygous for methionine tend to have FFI. In another kindred PrP gene, polymorphism was found to influence the age of disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/89\">",
"     89",
"    </a>",
"    ]. Despite these patterns, the clinical expression of individual mutations can vary even between affected members of the same family [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PRNP point mutations appear to influence the glycoform ratios and conformation of PrPSc; while these can differ among patients with the same inherited mutation, they are distinct from PrPSc seen in sporadic, iatrogenic, and variant CJD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/40\">",
"     40",
"    </a>",
"    ]. This may indicate that strain variation is a composite of both abnormal conformation and glycosylation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Familial CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In familial CJD (fCJD), a missense mutation involving the substitution of lysine for glutamine in codon 200 is the most common PRNP gene mutation, and this has been observed in many regions including from Libya, Chile, and Hungary [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. In Slovakia, this mutation underlies more than 70 percent of all prion diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/94\">",
"     94",
"    </a>",
"    ]. One study described a differing presentation of this syndrome with codon 129 phenotype changes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/95\">",
"     95",
"    </a>",
"    ]. When the mutant codon 200 was linked to a valine at codon 129, PrP deposits were observed in the cerebellum and the prion protein was resistant to type 2 protease, neither of which have been described with methionine at codon 129.",
"   </p>",
"   <p>",
"    As noted above, the D178N mutation occurs in fCJD as well as other prion diseases. A substitution of isoleucine for valine in codon 210 has also been noted in fCJD and was the most common PRNP mutation type observed among 104 cases of fCJD in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Other missense mutations as well as insertion mutations have been described as well [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/97-102\">",
"     97-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike fCJD, sporadic CJD (sCJD) and iatrogenic CJD (iCJD) are not associated with PRNP gene mutations. However, even in these forms of CJD and variant CJD (vCJD), phenotyping at codon 129 appears to affect susceptibility and perhaps expression of the clinical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/103\">",
"     103",
"    </a>",
"    ]. While 51 percent of the general population is heterozygous at codon 129, all cases of vCJD and 85 to 95 percent of individuals with sCJD have been found to be homozygous at this codon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/103\">",
"     103",
"    </a>",
"    ]. In a separate report, five of seven patients who developed iCJD after receiving human cadaveric growth hormone were homozygous at codon 129 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group has proposed a molecular classification scheme for sCJD based upon codon 129 polymorphism and characterization of the properties of PrPSc which was used to evaluate 300 sCJD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/105\">",
"     105",
"    </a>",
"    ]. As examples, a pattern of type 1 PrPSc plus at least one methionine at codon 129 was demonstrated in 70 percent while type 2 PrPSc plus codon 129 homozygous or heterozygous for valine was present in 25 percent and associated with ataxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link&amp;anchor=H15#H15\">",
"     \"Creutzfeldt-Jakob disease\", section on 'Molecular subtypes of sCJD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gerstmann-Str&auml;ussler-Scheinker syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;All GSS kindreds investigated to date have PRNP gene mutations. The P102L is the most common mutation and the one described in the descendants of the original family described by Gerstmann, Str&auml;ussler, and Scheinker [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. Many other mutations have been identified as well [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/109-114\">",
"     109-114",
"    </a>",
"    ]. As noted above, patients with some of these mutations have been clinically classified as fCJD or FFI rather than GSS.",
"   </p>",
"   <p>",
"    GSS exhibits a large degree of phenotypic heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/115\">",
"     115",
"    </a>",
"    ]. This may be partially due to differences in the underlying PRNP mutation. GSS patients with the P102L mutation, for example, may have more prominent cerebellar features [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/107\">",
"     107",
"    </a>",
"    ], while dementia may be a more prominent feature in patients with A117V, Y145STOP, and F198S mutations. Polymorphism at codon 129 may also play a modulating role in the manifestations of GSS in patients with the P102L mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. However, varied clinical expression of these diseases both between and within affected families with the same gene mutations suggests that other unidentified factors probably also are influential [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/115,117,118\">",
"     115,117,118",
"    </a>",
"    ]. A study of GSS patients with the P102L mutation, employing monoclonal antibodies that recognize wild-type but not mutant PrP, demonstrated a spectrum of involvement of wild-type as well as mutant PrP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/119\">",
"     119",
"    </a>",
"    ]. This may also contribute to the phenotypic variability seen in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fatal familial insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the D178N mutation has been the predominant mutation found in nearly all families with FFI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/120\">",
"     120",
"    </a>",
"    ]. This mutation also occurs in fCJD. It appears that patients with this mutation who are homozygous for methionine at codon 129 develop an FFI-like clinical syndrome whereas those homozygous for valine develop fCJD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Heterozygosity at codon 129 may prolong the duration and slow the temporal progression of FFI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7017/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7967336\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably once clinical symptoms appear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prions are small infectious pathogens containing protein but apparently lacking nucleic acid. The prion protein is the critical component of these agents and may, in fact, be its exclusive constituent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biology of prions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One characteristic feature of prions is their resistance to a number of normal decontaminating procedures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biology of prions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prion diseases appear to result from accumulation of abnormal isoforms of the prion protein, a membrane-bound glycophosphatidylinositol-anchored protein found in the brains of normal animals on both neuronal and non-neuronal cells. These changes are due to both variation in amino acid sequence as well as glycosylation of the prion protein. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prion protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transport of the abnormal prion protein to the nervous system, once it appears in the host, occurs via axons and appears to be neurotoxic; accumulation of this protein or fragments of it in neurons leads to apoptosis and cell death. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Transport of PrPSc to the nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gene encoding the prion protein in humans is located on the short arm of chromosome 20. A strong link was established between mutations in this gene and forms of prion disease with a familial predisposition (familial Creutzfeldt Jakob Disease, Gerstmann-Str&auml;ussler-Scheinker syndrome, and fatal familial insomnia). A single mutation can produce different clinical phenotypes in different individuals or families. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genetics of human prion diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/1\">",
"      Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/2\">",
"      McKintosh E, Tabrizi SJ, Collinge J. Prion diseases. J Neurovirol 2003; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/3\">",
"      Sy MS, Gambetti P, Wong BS. Human prion diseases. Med Clin North Am 2002; 86:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/4\">",
"      Glatzel M, Stoeck K, Seeger H, et al. Human prion diseases: molecular and clinical aspects. Arch Neurol 2005; 62:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/5\">",
"      O'Brien C. Mad cow disease. Scant data cause widespread concern. Science 1996; 271:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/6\">",
"      Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354:317.",
"     </a>",
"    </li>",
"    <li>",
"     Prusiner SB. The prion hypothesis. In: Prions, Prusiner, SB, McKinley, MP (Eds), Academic Press, San Diego 1987. p.17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/8\">",
"      Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/9\">",
"      Bellinger-Kawahara C, Diener TO, McKinley MP, et al. Purified scrapie prions resist inactivation by procedures that hydrolyze, modify, or shear nucleic acids. Virology 1987; 160:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/10\">",
"      Manuelidis L. Decontamination of Creutzfeldt-Jakob disease and other transmissible agents. J Neurovirol 1997; 3:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/11\">",
"      Taylor DM, Fernie K, McConnell I, Steele PJ. Observations on thermostable subpopulations of the unconventional agents that cause transmissible degenerative encephalopathies. Vet Microbiol 1998; 64:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/12\">",
"      Zobeley E, Flechsig E, Cozzio A, et al. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med 1999; 5:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/13\">",
"      Flechsig E, Hegyi I, Enari M, et al. Transmission of scrapie by steel-surface-bound prions. Mol Med 2001; 7:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/14\">",
"      Jackson GS, McKintosh E, Flechsig E, et al. An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol 2005; 86:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/15\">",
"      Baxter HC, Campbell GA, Whittaker AG, et al. Elimination of transmissible spongiform encephalopathy infectivity and decontamination of surgical instruments by using radio-frequency gas-plasma treatment. J Gen Virol 2005; 86:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/16\">",
"      Solassol J, Pastore M, Crozet C, et al. A novel copper-hydrogen peroxide formulation for prion decontamination. J Infect Dis 2006; 194:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/17\">",
"      Harris DA. Cellular biology of prion diseases. Clin Microbiol Rev 1999; 12:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/18\">",
"      Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987; 51:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/19\">",
"      Caughey B. Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nat Med 2000; 6:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/20\">",
"      Toni M, Massimino ML, Griffoni C, et al. Extracellular copper ions regulate cellular prion protein (PrPC) expression and metabolism in neuronal cells. FEBS Lett 2005; 579:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/21\">",
"      Brown DR, Wong BS, Hafiz F, et al. Normal prion protein has an activity like that of superoxide dismutase. Biochem J 1999; 344 Pt 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/22\">",
"      Sakudo A, Lee DC, Nishimura T, et al. Octapeptide repeat region and N-terminal half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of superoxide dismutase. Biochem Biophys Res Commun 2005; 326:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/23\">",
"      Solforosi L, Criado JR, McGavern DB, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004; 303:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/24\">",
"      Robertson C, Booth SA, Beniac DR, et al. Cellular prion protein is released on exosomes from activated platelets. Blood 2006; 107:3907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/25\">",
"      Isaacs JD, Jackson GS, Altmann DM. The role of the cellular prion protein in the immune system. Clin Exp Immunol 2006; 146:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/26\">",
"      Downing DT, Lazo ND. Molecular modelling indicates that the pathological conformations of prion proteins might be beta-helical. Biochem J 1999; 343 Pt 2:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/27\">",
"      Harrison PM, Chan HS, Prusiner SB, Cohen FE. Thermodynamics of model prions and its implications for the problem of prion protein folding. J Mol Biol 1999; 286:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/28\">",
"      Morillas M, Swietnicki W, Gambetti P, Surewicz WK. Membrane environment alters the conformational structure of the recombinant human prion protein. J Biol Chem 1999; 274:36859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/29\">",
"      Pierce MM, Baxa U, Steven AC, et al. Is the prion domain of soluble Ure2p unstructured? Biochemistry 2005; 44:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/30\">",
"      Prusiner SB, McKinley MP, Bowman KA, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983; 35:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/31\">",
"      Merz PA, Kascsak RJ, Rubenstein R, et al. Antisera to scrapie-associated fibril protein and prion protein decorate scrapie-associated fibrils. J Virol 1987; 61:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/32\">",
"      Jobling MF, Stewart LR, White AR, et al. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J Neurochem 1999; 73:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/33\">",
"      Ritter C, Maddelein ML, Siemer AB, et al. Correlation of structural elements and infectivity of the HET-s prion. Nature 2005; 435:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/34\">",
"      Harris DA, Huber MT, van Dijken P, et al. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993; 32:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/35\">",
"      Narwa R, Harris DA. Prion proteins carrying pathogenic mutations are resistant to phospholipase cleavage of their glycolipid anchors. Biochemistry 1999; 38:8770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/36\">",
"      Herms J, Tings T, Gall S, et al. Evidence of presynaptic location and function of the prion protein. J Neurosci 1999; 19:8866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/37\">",
"      Shyng SL, Huber MT, Harris DA. A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. J Biol Chem 1993; 268:15922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/38\">",
"      Hay B, Prusiner SB, Lingappa VR. Evidence for a secretory form of the cellular prion protein. Biochemistry 1987; 26:8110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/39\">",
"      Parchi P, Chen SG, Brown P, et al. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Str&auml;ussler-Scheinker disease. Proc Natl Acad Sci U S A 1998; 95:8322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/40\">",
"      Hill AF, Joiner S, Beck JA, et al. Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 2006; 129:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/41\">",
"      Lawson VA, Collins SJ, Masters CL, Hill AF. Prion protein glycosylation. J Neurochem 2005; 93:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/42\">",
"      Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 1992; 267:16188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/43\">",
"      Vey M, Pilkuhn S, Wille H, et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci U S A 1996; 93:14945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/44\">",
"      B&uuml;eler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/45\">",
"      B&uuml;eler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992; 356:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/46\">",
"      Soto C, Kascsak RJ, Sabor&iacute;o GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/47\">",
"      Kaneko K, Zulianello L, Scott M, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A 1997; 94:10069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/48\">",
"      Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/49\">",
"      Telling G. Anchors away--of plaques and pathology in prion disease. N Engl J Med 2005; 353:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/50\">",
"      Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem 1998; 67:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/51\">",
"      Tessier PM, Lindquist S. Prion recognition elements govern nucleation, strain specificity and species barriers. Nature 2007; 447:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/52\">",
"      Mabbott NA, Bruce ME, Botto M, et al. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 2001; 7:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/53\">",
"      Klein MA, Kaeser PS, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/54\">",
"      Khalili-Shirazi A, Quaratino S, Londei M, et al. Protein conformation significantly influences immune responses to prion protein. J Immunol 2005; 174:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/55\">",
"      Kimberlin RH, Walker CA. Pathogenesis of mouse scrapie: evidence for neural spread of infection to the CNS. J Gen Virol 1980; 51:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/56\">",
"      Fraser H, Dickinson AG. Targeting of scrapie lesions and spread of agent via the retino-tectal projection. Brain Res 1985; 346:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/57\">",
"      Borchelt DR, Koliatsos VE, Guarnieri M, et al. Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. J Biol Chem 1994; 269:14711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/58\">",
"      Rodolfo K, H&auml;ssig R, Moya KL, et al. A novel cellular prion protein isoform present in rapid anterograde axonal transport. Neuroreport 1999; 10:3639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/59\">",
"      Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 348:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/60\">",
"      Klein MA, Frigg R, Flechsig E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/61\">",
"      Crozet C, Lezmi S, Flamant F, et al. Peripheral circulation of the prion infectious agent in transgenic mice expressing the ovine prion protein gene in neurons only. J Infect Dis 2007; 195:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/62\">",
"      Kincaid AE, Bartz JC. The nasal cavity is a route for prion infection in hamsters. J Virol 2007; 81:4482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/63\">",
"      Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993; 362:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/64\">",
"      Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 1996; 380:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/65\">",
"      Jeffrey M, Goodsir CM, Race RE, Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Ann Neurol 2004; 55:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/66\">",
"      Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002; 298:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/67\">",
"      Hegde RS, Rane NS. Prion protein trafficking and the development of neurodegeneration. Trends Neurosci 2003; 26:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/68\">",
"      Serban D, Taraboulos A, DeArmond SJ, Prusiner SB. Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins. Neurology 1990; 40:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/69\">",
"      Safar J, Wille H, Itri V, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med 1998; 4:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/70\">",
"      Safar JG, Geschwind MD, Deering C, et al. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005; 102:3501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/71\">",
"      Castilla J, Sa&aacute; P, Soto C. Detection of prions in blood. Nat Med 2005; 11:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/72\">",
"      Sa&aacute; P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006; 313:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/73\">",
"      Paramithiotis E, Pinard M, Lawton T, et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/74\">",
"      Yang WC, Schmerr MJ, Jackman R, et al. Capillary electrophoresis-based noncompetitive immunoassay for the prion protein using fluorescein-labeled protein A as a fluorescent probe. Anal Chem 2005; 77:4489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/75\">",
"      Gofflot S, Deprez M, el Moualij B, et al. Immunoquantitative PCR for prion protein detection in sporadic Creutzfeldt-Jakob disease. Clin Chem 2005; 51:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/76\">",
"      Tcherkasskaya O, Davidson EA, Schmerr MJ, Orser CS. Conformational biosensor for diagnosis of prion diseases. Biotechnol Lett 2005; 27:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/77\">",
"      Birkmann E, Sch&auml;fer O, Weinmann N, et al. Detection of prion particles in samples of BSE and scrapie by fluorescence correlation spectroscopy without proteinase K digestion. Biol Chem 2006; 387:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/78\">",
"      Sakudo A, Nakamura I, Ikuta K, Onodera T. Recent developments in prion disease research: diagnostic tools and in vitro cell culture models. J Vet Med Sci 2007; 69:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/79\">",
"      Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011; 17:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/80\">",
"      Sparkes RS, Simon M, Cohn VH, et al. Assignment of the human and mouse prion protein genes to homologous chromosomes. Proc Natl Acad Sci U S A 1986; 83:7358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/81\">",
"      Wadsworth JD, Hill AF, Beck JA, Collinge J. Molecular and clinical classification of human prion disease. Br Med Bull 2003; 66:241.",
"     </a>",
"    </li>",
"    <li>",
"     Kong Q, Surewicz WK, Petersen RB, et al. Inherited prion diseases. In: Prion biology and disease, 2nd, Prusiner SB (Ed), Cold Spring Harbor Laboratory Press, New York 2004. p.673.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/83\">",
"      Saitoh Y, Ogawa M, Naito Y, et al. Discordant clinicopathologic phenotypes in a Japanese kindred of fatal familial insomnia. Neurology 2010; 74:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/84\">",
"      Synofzik M, Bauer P, Sch&ouml;ls L. Prion mutation D178N with highly variable disease onset and phenotype. J Neurol Neurosurg Psychiatry 2009; 80:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/85\">",
"      Mallucci GR, Campbell TA, Dickinson A, et al. Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene. Brain 1999; 122 ( Pt 10):1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/86\">",
"      McLean CA, Storey E, Gardner RJ, et al. The D178N (cis-129M) \"fatal familial insomnia\" mutation associated with diverse clinicopathologic phenotypes in an Australian kindred. Neurology 1997; 49:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/87\">",
"      Gambetti P. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: a tale of two diseases with the same genetic mutation. Curr Top Microbiol Immunol 1996; 207:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/88\">",
"      Zarranz JJ, Digon A, Atar&eacute;s B, et al. Phenotypic variability in familial prion diseases due to the D178N mutation. J Neurol Neurosurg Psychiatry 2005; 76:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/89\">",
"      Mead S, Poulter M, Beck J, et al. Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneity. Brain 2006; 129:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/90\">",
"      Monari L, Chen SG, Brown P, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci U S A 1994; 91:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/91\">",
"      Meiner Z, Gabizon R, Prusiner SB. Familial Creutzfeldt-Jakob disease. Codon 200 prion disease in Libyan Jews. Medicine (Baltimore) 1997; 76:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/92\">",
"      Brown P, G&aacute;lvez S, Goldfarb LG, et al. Familial Creutzfeldt-Jakob disease in Chile is associated with the codon 200 mutation of the PRNP amyloid precursor gene on chromosome 20. J Neurol Sci 1992; 112:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/93\">",
"      Kov&aacute;cs GG, L&aacute;szl&oacute; L, Bakos A, et al. Increased incidence of genetic human prion disease in Hungary. Neurology 2005; 65:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/94\">",
"      Mitrov&aacute; E, Belay G. Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development. Acta Virol 2002; 46:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/95\">",
"      Hainfellner JA, Parchi P, Kitamoto T, et al. A novel phenotype in familial Creutzfeldt-Jakob disease: prion protein gene E200K mutation coupled with valine at codon 129 and type 2 protease-resistant prion protein. Ann Neurol 1999; 45:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/96\">",
"      Prusiner SB. Prion diseases and the BSE crisis. Science 1997; 278:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/97\">",
"      Ladogana A, Puopolo M, Poleggi A, et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005; 64:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/98\">",
"      Basset-Leobon C, Uro-Coste E, Peoc'h K, et al. Familial Creutzfeldt-Jakob disease with an R208H-129V haplotype and Kuru plaques. Arch Neurol 2006; 63:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/99\">",
"      Wang XF, Guo YJ, Zhang BY, et al. Creutzfeldt-Jakob disease in a Chinese patient with a novel seven extra-repeat insertion in PRNP. J Neurol Neurosurg Psychiatry 2007; 78:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/100\">",
"      Kov&aacute;cs T, Beck JA, Papp MI, et al. Familial prion disease in a Hungarian family with a novel 144-base pair insertion in the prion protein gene. J Neurol Neurosurg Psychiatry 2007; 78:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/101\">",
"      S&aacute;nchez-Valle R, Ar&oacute;stegui JI, Yag&uuml;e J, et al. First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. J Neurol Neurosurg Psychiatry 2008; 79:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/102\">",
"      Jansen C, van Swieten JC, Capellari S, et al. Inherited Creutzfeldt-Jakob disease in a Dutch patient with a novel five octapeptide repeat insertion and unusual cerebellar morphology. J Neurol Neurosurg Psychiatry 2009; 80:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/103\">",
"      Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991; 352:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/104\">",
"      Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/105\">",
"      Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/106\">",
"      Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Str&auml;ussler syndrome. Nature 1989; 338:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/107\">",
"      Kretzschmar HA, Kufer P, Riethm&uuml;ller G, et al. Prion protein mutation at codon 102 in an Italian family with Gerstmann-Str&auml;ussler-Scheinker syndrome. Neurology 1992; 42:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/108\">",
"      Hainfellner JA, Brantner-Inthaler S, Cerven&aacute;kov&aacute; L, et al. The original Gerstmann-Str&auml;ussler-Scheinker family of Austria: divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol 1995; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     Gajdusek DC. Infectious amyloids: Subacute spongiform encephalopathies as transmissible cerebral amyloidoses. In: Fields Virology, 3rd, Fields, BN, Knipe, DM, Howley, PM (Eds), Lippincott-Raven, New York 1996. p.2851.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/110\">",
"      Collinge J. Inherited prion diseases. Adv Neurol 1993; 61:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/111\">",
"      Panegyres PK, Toufexis K, Kakulas BA, et al. A new PRNP mutation (G131V) associated with Gerstmann-Str&auml;ussler-Scheinker disease. Arch Neurol 2001; 58:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/112\">",
"      Piccardo P, Liepnieks JJ, William A, et al. Prion proteins with different conformations accumulate in Gerstmann-Str&auml;ussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol 2001; 158:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/113\">",
"      Rowe DB, Lewis V, Needham M, et al. Novel prion protein gene mutation presenting with subacute PSP-like syndrome. Neurology 2007; 68:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/114\">",
"      Hinnell C, Coulthart MB, Jansen GH, et al. Gerstmann-Straussler-Scheinker disease due to a novel prion protein gene mutation. Neurology 2011; 76:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/115\">",
"      Webb TE, Poulter M, Beck J, et al. Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 2008; 131:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/116\">",
"      Young K, Jones CK, Piccardo P, et al. Gerstmann-Str&auml;ussler-Scheinker disease with mutation at codon 102 and methionine at codon 129 of PRNP in previously unreported patients. Neurology 1995; 45:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/117\">",
"      Barbanti P, Fabbrini G, Salvatore M, et al. Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann-Str&auml;ussler-Scheinker disease (PrP-P102L mutation). Neurology 1996; 47:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/118\">",
"      Tanaka Y, Minematsu K, Moriyasu H, et al. A Japanese family with a variant of Gerstmann-Str&auml;ussler-Scheinker disease. J Neurol Neurosurg Psychiatry 1997; 62:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/119\">",
"      Wadsworth JD, Joiner S, Linehan JM, et al. Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain 2006; 129:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/120\">",
"      Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992; 326:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7017/abstract/121\">",
"      Krasnianski A, Bartl M, Sanchez Juan PJ, et al. Fatal familial insomnia: Clinical features and early identification. Ann Neurol 2008; 63:658.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5077 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7017=[""].join("\n");
var outline_f6_54_7017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7967336\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY OF PRIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prion protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Biosynthesis of PrPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Conversion of PrPC to PrPSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Possible role for immune response in early pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transport of PrPSc to the nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurotoxicity of prion protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Demonstration of PrPSc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENETICS OF HUMAN PRION DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Familial CJD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gerstmann-Str&auml;ussler-Scheinker syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fatal familial insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7967336\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_54_7018="Treatment and prognosis of diastolic heart failure";
var content_f6_54_7018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of diastolic heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7018/contributors\">",
"     Michael R Zile, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7018/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7018/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/54/7018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/54/7018/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/54/7018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastolic heart failure (DHF) is a major cause of heart failure with preserved ejection fraction (HF-PEF) (",
"    <a class=\"graphic graphic_table graphicRef54975 \" href=\"UTD.htm?19/7/19580\">",
"     table 1",
"    </a>",
"    ). DHF is a clinical syndrome in which patients have symptoms and signs of heart failure (HF), normal or near normal left ventricular (LV) systolic function, and evidence of diastolic dysfunction (eg, abnormal LV filling and elevated filling pressures) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prognosis of patients with DHF will be reviewed here. Issues related to etiology, clinical manifestations, diagnosis, and pathophysiology are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=see_link\">",
"     \"Cellular mechanisms of diastolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPAIRED RESPONSE TO STRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diastolic heart failure have particular difficulty in tolerating certain kinds of hemodynamic stress:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They tolerate atrial fibrillation (AF) poorly, since the loss of atrial contraction can dramatically reduce left atrial emptying, LV filling, and LV stroke volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They do not tolerate tachycardia well, since the increase in heart rate shortens the duration of diastole and truncates relaxation, pressure decline, recoil and diastolic filling.",
"     </li>",
"     <li>",
"      Elevations in systemic blood pressure, especially the abrupt, severe, or refractory elevations often seen with renovascular hypertension, increase left ventricular wall stress, which can worsen myocardial relaxation in patients with DHF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment of hypertension in patients with heart failure\", section on 'Diastolic dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The acute induction or worsening of diastolic dysfunction by ischemia raises left atrial and therefore pulmonary venous pressure. This explains why many patients with coronary heart disease (CHD) have respiratory symptoms with their anginal pain, including wheezing, an inability to take a deep breath, shortness of breath, and overt pulmonary edema. These respiratory symptoms can occur in the absence of anginal pain and are often referred to as \"anginal equivalents.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Episodes of hemodynamic decompensation may result in pulmonary congestion or edema severe enough to be life-threatening. This phenomenon, called flash pulmonary edema, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .) Studies using implantable hemodynamic monitors have shown that LV diastolic pressures rise in a progressive fashion prior to apparent abrupt onset of acute heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. While the development of symptoms is rapid, the increases in diastolic pressure occur gradually over a period of weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of diastolic heart failure (DHF) remains empiric, since trial data are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for treatment of patients with DHF were published in 2005 by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force on chronic HF (",
"    <a class=\"graphic graphic_table graphicRef70468 \" href=\"UTD.htm?8/7/8316\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/9\">",
"     9",
"    </a>",
"    ]. It was concluded that the weight of evidence supported only four modalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Control of systolic and diastolic hypertension",
"     </li>",
"     <li>",
"      Control of ventricular rate in patients with atrial fibrillation",
"     </li>",
"     <li>",
"      Control of pulmonary congestion and peripheral edema with diuretics and nitrates",
"     </li>",
"     <li>",
"      Coronary revascularization in patients with CHD in whom ischemia is judged to have an adverse effect on diastolic function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A clinical practice review concurred with the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and provided specific examples of clinical therapies appropriate to achieving these goals (",
"    <a class=\"graphic graphic_table graphicRef51637 \" href=\"UTD.htm?40/17/41244\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumococcal vaccination is recommended for all patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Annual influenza vaccination is now recommended for all individuals 6 months of age and older. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Choice of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of medications in patients with DHF is determined by two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of specific underlying processes such as hypertension or symptomatic CHD. Combined therapy may be warranted since hypertrophied hearts are more sensitive to the deleterious effects of ischemia on LV relaxation than nonhypertrophied hearts [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"       \"Pathophysiology of diastolic heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The possibly beneficial effect of the drug on the pathophysiology of DHF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines concluded that efficacy was less well established for the administration of specific drugs, such as beta blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important caveat is that the patient who has LV diastolic dysfunction with a small, stiff left ventricular chamber is particularly susceptible to excessive preload reduction, which can lead sequentially to underfilling of the LV, a fall in cardiac output, and hypotension. In patients with severe left ventricular hypertrophy (LVH) due to hypertension or hypertrophic cardiomyopathy, excessive preload reduction can also create subaortic outflow obstruction.",
"   </p>",
"   <p>",
"    For these reasons, the administration of diuretics or venodilators such as nitrates and dihydropyridine calcium channel blockers must be performed with caution. Careful attention is required for symptoms of ventricular underfilling such as weakness, dizziness, near syncope, and syncope.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is generally not used in patients with DHF because systolic function is intact. The DIG ancillary trial, a parallel study to the DIG trial, evaluated the role of digoxin in patients with HF and an LVEF &gt;45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. At a mean follow-up of 37 months, digoxin had no effect on all-cause or cause-specific mortality, or all-cause or cardiovascular hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lowering the systemic blood pressure was associated with reduced rate of HF in some large randomized hypertension treatment trials, particularly those including diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The choice of a specific antihypertensive agent must be individualized in the presence of coexisting diseases such as diabetes mellitus or chronic obstructive pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regression of LVH is an important therapeutic goal, since it may improve diastolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/17\">",
"     17",
"    </a>",
"    ]. A meta-analysis published in 2003 attempted to evaluate the relative efficacy of different antihypertensive drugs for their ability to reverse LVH in patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/18\">",
"     18",
"    </a>",
"    ]. Eighty trials that included 146 and 17 active treatment and placebo arms, respectively, were evaluated. After statistical adjustments for length of therapy and degree of blood pressure lowering, the relative reductions in left ventricular mass index were (",
"    <a class=\"graphic graphic_figure graphicRef82558 \" href=\"UTD.htm?42/42/43693\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) - 13 percent",
"     </li>",
"     <li>",
"      Calcium channel blockers - 11 percent",
"     </li>",
"     <li>",
"      ACE inhibitors - 10 percent",
"     </li>",
"     <li>",
"      Diuretics - 8 percent",
"     </li>",
"     <li>",
"      Beta blockers - 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ARBs, calcium channel blockers, and ACE inhibitors produced more regression than beta blockers. The clinical significance of this difference is uncertain since there is as yet no evidence that more rapid regression of LVH is associated with improved long-term outcomes. The choice of antihypertensive therapy is usually based upon other factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV filling in DHF occurs largely in late diastole and is therefore more dependent than normal hearts on atrial contraction. Tachycardia is also deleterious by shortening the time of diastole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, restoration and maintenance of sinus rhythm is preferred when AF occurs in patients with DHF. When this cannot be achieved, rate control becomes important. Beta blockers and calcium channel blockers are the usual first-line agents, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    most often being used in patients with systolic HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A combination of these drugs may be required to achieve adequate heart rate control. It is important to measure heart rate during moderate exercise and not to base heart rate control solely on values obtained in the resting state.",
"   </p>",
"   <p>",
"    An important component of the management of atrial fibrillation, regardless of whether rhythm control or rate control is chosen, is anticoagulation to prevent systemic embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antiischemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial ischemia often precipitates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contributes to DHF. Ischemia can result from CHD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LVH with subendocardial ischemia. In such patients, beta blockers and calcium channel blockers are preferred. Nitrates are also effective but, as mentioned above, the reduction in preload can lead to hypotension in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Revascularization by percutaneous coronary intervention or coronary artery bypass graft surgery may be required in patients with drug-resistant ischemic DHF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers have a variety of potential beneficial effects in patients with DHF including slowing the heart rate (which increases the time available for both LV filling and coronary flow, particularly during exercise), reducing myocardial oxygen demand, and, by lowering the blood pressure, causing regression of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Slowing the heart rate is particularly important in the treatment of pulmonary congestion due to ischemic DHF and, as noted above, in patients in atrial fibrillation.",
"   </p>",
"   <p>",
"    In the small SWEDIC trial, 113 patients with symptoms of HF, normal left ventricular ejection fraction, and abnormal diastolic function were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    or placebo, with echocardiographic assessment at baseline and six months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/21\">",
"     21",
"    </a>",
"    ]. Carvedilol therapy resulted in a significant improvement in the",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio, but no significant improvement in deceleration time, isovolumic relaxation time, or pulmonary vein flow velocity.",
"   </p>",
"   <p>",
"    Beta blockers may also directly improve diastolic function in patients with idiopathic dilated cardiomyopathy and those with an acute myocardial infarction; both are settings in which beta blockers are recommended because they improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Slowing of the heart rate may contribute to this effect by providing more time for calcium exit from myocytes, thereby reversing the cellular calcium overload characteristic of diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=see_link\">",
"     \"Cellular mechanisms of diastolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, direct evidence of the clinical efficacy of beta blocker therapy in patients with DHF is lacking. While the SENIORS trial suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/34/32295?source=see_link\">",
"     nebivolol",
"    </a>",
"    (a beta blocker with vasodilating properties) may be beneficial in patients with HF and preserved systolic function, an OPTIMIZE-HF registry study found no clinical benefit of beta blocker therapy in this population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SENIORS trial, 2128 patients &ge;70 years of age with history of HF or known LVEF &le;35 percent were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/34/32295?source=see_link\">",
"       nebivolol",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/24\">",
"       24",
"      </a>",
"      ]. Nebivolol therapy resulted in reduction in the primary outcome of all cause mortality or cardiovascular hospital admission (31 versus 35 percent) at mean 21 month follow-up. While the majority of study patients had LVEF &le;35 percent, there was no significant influence of ejection fraction on the effect of nebivolol on the outcome. The effect of nebivolol on outcomes was similar in those with preserved and impaired LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, a difference in the clinical efficacy of beta blocker therapy in patients with systolic HF versus patients with DHF was suggested by a retrospective study from the OPTIMIZE-HF registry of 7154 elderly adults hospitalized with HF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/26\">",
"       26",
"      </a>",
"      ]. Among patients with left ventricular systolic dysfunction, beta blocker therapy was associated with reduced mortality and rehospitalization rates. In contrast, among patients with preserved systolic function, beta blocker therapy was associated with no improvement in mortality or rehospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, there is no good demonstration that beta blockade is beneficial in the treatment of DHF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers may also be useful in the treatment of DHF. These agents have been purported to have a direct \"lusitropic\" (relaxation-enhancing) effect. However, it is difficult to distinguish this effect from the benefits related to slowing of the heart rate, both at rest and during exercise, and to a reduction in or prevention of ischemic episodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9816?source=see_link\">",
"     \"Calcium channel blockers in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations from small studies are consistent with the possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small randomized, crossover trial of 20 patients with DHF,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , compared to placebo, significantly reduced the signs and symptoms of HF and increased LV diastolic filling rate and treadmill exercise time [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with hypertrophic cardiomyopathy (HCM),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      can improve LV diastolic function and may prolong long-term survival [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. In a report of 55 patients with HCM who were treated with verapamil (360 to 480",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for one to four weeks, an increase in peak LV diastolic filling rate occurred in 43 (78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/28\">",
"       28",
"      </a>",
"      ]. Objective symptomatic improvement on graded exercise testing occurred in 34 of these patients compared to only 1 of 12 without an increase in diastolic filling rate (79 versus 12 percent). These benefits persisted for one to two years, and were reversed when therapy was discontinued. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"       \"Medical therapy in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence from randomized clinical studies that ACE inhibitor therapy directly improves overall morbidity or mortality in patients with DHF. Because patients with DHF frequently have co-morbidities such as renal insufficiency, ACE inhibitors should be used carefully to avoid the risk of renal dysfunction and hypotension. Despite these concerns, ACE inhibitors play an important role in the treatment of the disease processes that underlie the development of DHF, namely, hypertension, coronary artery disease and diabetes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors are beneficial in hypertensive heart disease. The reduction in systemic pressure can lead to regression of left ventricular hypertrophy (LVH) and a gradual improvement in diastolic function (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Antihypertensive therapy'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/18,30\">",
"       18,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACE inhibitors are beneficial in patients with mixed systolic and DHF. They are indicated in patients with systolic HF, since they slow the rate of progression of the myocardial disease and improve survival. In such patients, ACE inhibitors also prevent progression of diastolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The more general efficacy of ACE inhibitors in patients with DHF was assessed in the PEP-CHF trial in which 850 patients &ge;70 years of age with diastolic dysfunction: 79 percent had a history of hypertension; patients with substantial LV systolic dysfunction or valve disease were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/32\">",
"     32",
"    </a>",
"    ]. The patients were randomly assigned to an ACE inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    ) or placebo. At one year, treatment with perindopril was associated with an almost significant trend toward reduction in the primary end point of combined all-cause mortality and unexpected hospitalization for HF (8.0 versus 12.4 percent, HR 0.69; 95% CI 0.47-1.01); this effect was entirely due to fewer unexpected hospitalizations for HF. The patients treated with perindopril also had significant improvements in functional class and six minute walk distance.",
"   </p>",
"   <p>",
"    While benefit from ACE inhibitors may be mediated by its blood pressure effects, it is also possible that there might be a reduction in myocardial angiotensin II production, which can diminish myocardial stiffness. Evidence in support of this hypothesis has been provided by a study of patients with DHF due to aortic stenosis-induced LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/33\">",
"     33",
"    </a>",
"    ]. The intracoronary infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"     enalaprilat",
"    </a>",
"    , which produced no evidence of systemic ACE inhibition but presumably impaired cardiac angiotensin II production, improved diastolic distensibility and relaxation. Similar benefits may occur in patients with ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/34\">",
"     34",
"    </a>",
"    ] and during experimental low-flow ischemia in hypertrophied hearts with ischemic diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence from randomized clinical studies that ARB therapy directly improves overall morbidity or mortality in patients with DHF. There is no clear evidence of improved diastolic function with angiotensin II receptor blocker treatment as compared to other therapies in patients with asymptomatic left ventricular diastolic dysfunction or overt DHF.",
"   </p>",
"   <p>",
"    Angiotensin II receptor blockers (ARBs) may be beneficial in patients with left ventricular diastolic dysfunction due to hypertension, although the data on impact compared to other agents are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/17,18,35-38\">",
"     17,18,35-38",
"    </a>",
"    ]. In various studies of hypertensive patients with LVH, ARBs caused more regression of LVH than beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/18,36\">",
"     18,36",
"    </a>",
"    ], a change that was associated with an improvement in LV diastolic filling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/17\">",
"     17",
"    </a>",
"    ]. In other studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    treatment improved exercise tolerance and quality of life (which were not improved by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/37\">",
"     37",
"    </a>",
"    ] and reduced myocardial fibrosis and stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\", section on 'Effect of antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a large randomized trial in patients with hypertension and diastolic dysfunction demonstrated that improvement in diastolic function with angiotensin II receptor blocker therapy was similar to that with other antihypertensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/39\">",
"     39",
"    </a>",
"    ]. The trial included 382 patients who were treated with antihypertensive drugs not related to angiotensin inhibition and then randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/39\">",
"     39",
"    </a>",
"    ]. There were similar improvements in the two groups in blood pressure control and diastolic function, as measured by myocardial relaxation velocity of the lateral mitral annulus (E').",
"   </p>",
"   <p>",
"    Outcomes of treatment with angiotensin II receptor blockers in patients with HF and preserved left ventricular ejection fraction (LVEF) were investigated in two large trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CHARM-Preserved trial, 3023 patients with symptomatic HF (nearly all NYHA class II or III) and an LVEF &gt;40 percent were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      (mean dose at six months 25 mg) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/40\">",
"       40",
"      </a>",
"      ]. The mean LVEF was 54 percent. Additional medications included ACE inhibitor in 19 percent, beta blocker in 56 percent, and calcium channel blocker in 31 percent.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 37 months, there was a small and almost significant difference in incidence of the primary end point of cardiovascular death or hospitalization for HF (22 versus 24 percent; adjusted hazard ratio 0.86; 95% CI 0.74-1.00) that was entirely due to a significant reduction in hospitalization for HF with candesartan (16 versus 18 percent). The overall rate of discontinuation of therapy was similar in the two groups (22 versus 18 percent). However, significantly more patients discontinued candesartan because of renal dysfunction, hyperkalemia, or hypotension.",
"     </li>",
"     <li>",
"      In the I-PRESERVE trial, 4128 patients with symptomatic HF (nearly all NYHA class II or III) and an LVEF &ge;45 percent were randomly assigned to either daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"       irbesartan",
"      </a>",
"      300 mg or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/41\">",
"       41",
"      </a>",
"      ]. The mean LVEF was 59 percent. Additional medications included ACE inhibitor in 26 percent, beta blocker in 59 percent, and calcium channel blocker in 40 percent.",
"      <br/>",
"      <br/>",
"      At a mean follow-up of 49.5 months, there was no significant difference in the primary end point of death from any cause or hospitalization for a cardiovascular cause. There were also no significant differences in secondary outcomes which included death from HF or hospitalization for heart failure, death from any cause, hospitalization for a cardiovascular cause, and quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone contributes to cardiac hypertrophy and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These processes may be preventable or even reversible by aldosterone blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible benefit of aldosterone antagonism in DHF was suggested in a study of 30 medically treated patients with exertional dyspnea, an LVEF &gt;50 percent, and diastolic dysfunction who were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/47\">",
"     47",
"    </a>",
"    ]. At six months, spironolactone therapy was associated with significant improvement in myocardial function by echocardiographic indices, including strain rate, peak systolic strain, and cyclic variation of integrated backscatter.",
"   </p>",
"   <p>",
"    A large NIH sponsored study, TOPCAT, is evaluating the hypothesis that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    is beneficial in patients with a normal ejection fraction and heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5713896\">",
"    <span class=\"h2\">",
"     Phosphodiesterase-5 inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beneficial hemodynamic response to the phosphodiesterase-5 inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    (50 mg three times per day) was observed in a randomized placebo-controlled trial of 44 patients with DHF with LVEF &ge;50 percent and pulmonary hypertension (pulmonary artery systolic pressure &gt;40 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/48\">",
"     48",
"    </a>",
"    ]. At six months, there was no response to placebo but sildenafil led to significant improvements in mean pulmonary artery pressure (reduced by 16.7 mmHg), right ventricular function (7.9 mm increase in mean tricuspid annular systolic excursion), and mean right atrial pressure (reduced by 12.4 mm). Quality of life measures of breathlessness, fatigue, and emotional function were significantly improved with sildenafil but not placebo. Similar results were observed at 12 months. These findings require confirmation in a larger trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive lipid lowering with statin therapy is recommended for the secondary prevention of cardiovascular disease, independent of the presence of diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial observational data suggest that statins might be of benefit in patients with DHF. Randomized trials are required to confirm these observations. Statin therapy in patients with HF is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=see_link\">",
"     \"Statin therapy in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Exercise conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;During exercise in healthy individuals, diastolic function is enhanced so that left ventricular input remains precisely matched to LV output, despite the shortened duration of diastole resulting from the associated tachycardia. This is achieved in the normal LV by a rapid and marked decrease in intraventricular pressure during early diastole, thereby creating a greater LV \"suction\" effect, which enhances the transmitral pressure gradient without increasing left atrial pressure and compromising pulmonary function. This mechanism is lost in patients with diastolic dysfunction; as a result, dyspnea with exertion is often their most common complaint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology of diastolic heart failure\", section on 'Normal response to exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term exercise training produces physiologic cardiac hypertrophy with enhanced diastolic function. Experimental studies suggest that exercise conditioning has the potential to reverse the diastolic dysfunction of pathologic LVH or aging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small randomized trials suggest that exercise training improves functional capacity in patients with heart failure with preserved left ventricular ejection fraction (HF-PEF, which is largely attributed to DHF). This evidence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac rehabilitation in patients with heart failure\", section on 'Effect on functional capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any exercise training program for the potential treatment of DHF should be based upon dynamic isotonic exercise, not static exercise, since the latter causes changes in cardiac geometry similar to those of hypertensive LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369455524\">",
"    <span class=\"h2\">",
"     Implantable hemodynamic monitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed separately, a randomized trial found that use of an implantable hemodynamic monitor (IHM) decreased heart failure hospitalizations in a population of patients that included patients with DHF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=see_link&amp;anchor=H23#H23\">",
"     \"Possibly effective emerging therapies for heart failure\", section on 'Outpatient monitoring via device'",
"    </a>",
"    .) While such devices are not yet available for clinical use, they are currently being evaluated by the FDA. The reasons for possible efficacy are unknown, but may include more aggressive titration of medications as well as earlier recognition of problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369455754\">",
"    <span class=\"h2\">",
"     Treatment differences between SHF and DHF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the randomized clinical trials in patients with DHF (or HFPEF) have demonstrated that while neurohumoral antagonists such as beta blockers, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers are effective in treatment of systolic heart failure (SHF), they do not decrease morbidity and mortality in DHF. These data suggest that there are fundamental differences in the pathophysiology underlying SHF versus DHF. In addition, these data suggest that future studies should target different and novel mechanisms in DHF. When choosing medications for hypertension, co-morbidities should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic diastolic dysfunction is a predictor of future cardiovascular morbidity, but prognosis differs from that in patients with symptoms of heart failure (ie, DHF). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13537491\">",
"    <span class=\"h2\">",
"     Asymptomatic diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe diastolic dysfunction without HF is a predictor of mortality as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Mayo Clinic cross-sectional community survey of 2042 adults &ge;45 years of age, 21 percent had mild diastolic dysfunction, 7 percent had moderate diastolic dysfunction, and 1 percent had severe diastolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/54\">",
"       54",
"      </a>",
"      ]. At a median follow-up of 3.5 years, 48 subjects died. After controlling for age, sex, and LVEF, all-cause mortality was increased in patients with mild diastolic dysfunction (96 percent without a diagnosis of HF; hazard ratio 8.3) and in those with moderate to severe diastolic dysfunction (90 percent without a diagnosis of HF; hazard ratio 10.2).",
"     </li>",
"     <li>",
"      In another report, 3008 Native Americans 45 to 74 years of age were followed for three years following Doppler echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/55\">",
"       55",
"      </a>",
"      ]. The 16 percent of patients had an",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &lt;0.6 (impaired diastolic relaxation) and 3 percent had an",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &gt;1.5 (restrictive pattern due to reduced compliance) (",
"      <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"       waveform 1",
"      </a>",
"      ). After adjustment for covariates, an",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &gt;1.5, but not an",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &lt;0.6, was independently associated with all-cause and cardiac mortality (relative risks 1.7 and 2.8, respectively).",
"     </li>",
"     <li>",
"      A Cleveland Clinic study followed 36,261 adults (mean age 58) with LVEF &ge;55 percent for a mean of 6.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/56\">",
"       56",
"      </a>",
"      ]. Sixty percent had mild diastolic dysfunction, 4.8 percent had moderate diastolic dysfunction, and 0.4 percent had severe diastolic dysfunction. 5789 deaths occurred during the follow-up period. Moderate and severe (but not mild) diastolic dysfunction were independent risk factors for mortality after adjustment for cardiovascular risk factors and comorbidities (HR 1.58; 95% CI 1.20-1.28 and HR 1.84; 1.29-2.62).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Symptomatic patients (ie, DHF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with symptomatic DHF is less well defined than in that of patients with systolic HF. Data from the Framingham Heart Study, the V-HeFT trials, and several observational series revealed varying results [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/57-64\">",
"     57-64",
"    </a>",
"    ]. In addition, the data are not clear on whether the long-term prognosis differs between diastolic and systolic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In reports from the community-based Framingham Heart study and the larger Cardiovascular Health Study, prognosis was significantly better in patients with diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/59,61\">",
"     59,61",
"    </a>",
"    ]. In the latter study of 269 patients at least 65 years of age who had HF, the mortality rates were 87 versus 154 deaths per 1000 person-years with normal and impaired systolic function, respectively (adjusted hazard ratio 1.48 and 1.88 compared to persons with no HF and normal left ventricular systolic function) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, another community-based study from Olmsted County, Minnesota found that, after adjustment for risk factors, five-year survival was not significantly different in patients with diastolic versus systolic HF (adjusted relative risk 0.80, p = 0.37) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients hospitalized for HF, the mortality rates are higher but the data are again conflicting as to whether or not the prognosis is different in diastolic and systolic HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 6076 patients discharged from a Mayo Clinic Hospitals in Olmsted County, Minnesota with a diagnosis of decompensated HF over a 15 year period (1987-2001), 53 percent had a reduced LVEF and 47 percent had a preserved LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/58\">",
"       58",
"      </a>",
"      ]. One-year mortality was relatively high in both groups, but slightly lower in patients with a preserved LVEF (29 versus 32 percent in patients with reduced LVEF, adjusted hazard ratio 0.96, 95% CI 0.92-1.00). Survival improved over time for those with reduced left ventricular ejection fraction (LVEF) but not for those with preserved LVEF.",
"     </li>",
"     <li>",
"      In a prospective evaluation of 413 patients hospitalized for HF, the relative risk for six month mortality was lower for diastolic versus systolic HF dysfunction (13 versus 21 percent, adjusted hazard ratio 0.51) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 2802 patients discharged from 103 hospitals in Ontario with a diagnosis of decompensated HF, one-year mortality was 22 percent in patients with a preserved LVEF versus 26 percent in patients with a reduced LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/64\">",
"       64",
"      </a>",
"      ]. This difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent predictors of mortality in patients with DHF in different studies include older age, male gender, NYHA class, lower LVEF, the extent of coronary artery disease, peripheral artery disease, diabetes, impaired renal function, the degree of diastolic dysfunction as assessed by Doppler echocardiography, and increased red cell distribution width [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/66-71\">",
"     66-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26872914\">",
"    <span class=\"h3\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of death was evaluated in patients with symptomatic DHF (NYHA class II to IV HF with LVEF &ge;45 percent) enrolled in the I-Preserve trial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/72\">",
"     72",
"    </a>",
"    ]. The annual mortality rate was 5 percent. Sixty percent of deaths were cardiovascular (26 percent sudden, 14 percent HF, 5 percent myocardial infarction, and 9 percent stroke), 30 percent were noncardiovascular (including cancer and",
"    <span class=\"nowrap\">",
"     infection/sepsis),",
"    </span>",
"    and 10 percent were of unknown cause.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    treatment did not affect the mortality rate or the distribution of mode of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39061108\">",
"    <span class=\"h3\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly every study that has compared morbidity outcomes in SHF and DHF have found equivalent rates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/54/7018/abstract/64,73-77\">",
"     64,73-77",
"    </a>",
"    ]. These include the rate and frequency of hospitalization for heart failure, symptomatic status as measured by abnormalities in myocardial oxygen consumption, six-minute walk distance, Minnesota Living with Heart Failure questionnaire (MLHFQ) scores, and other quality of life indicators. Therefore, patients with DHF have a morbidity burden equivalent to that in patients with SHF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"       \"Patient information: Heart failure and atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8053301\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with diastolic heart failure (DHF), certain types of hemodynamic stress including atrial fibrillation; tachycardia; abrupt, severe, or refractory elevations in systemic blood pressure, and myocardial ischemia are associated with worsening of diastolic dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Impaired response to stress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of DHF remains empiric since trial data are limited. The general principles for treatment of DHF are control of systolic and diastolic hypertension, control of ventricular rate, particularly in patients with atrial fibrillation, control of pulmonary congestion and peripheral edema with diuretics, and coronary revascularization in patients with coronary heart disease with ischemia judged to impair diastolic function. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important caveat is that the patient who has LV diastolic dysfunction with a small, stiff left ventricular chamber is particularly susceptible to excessive preload reduction, which can lead sequentially to underfilling of the LV, a fall in cardiac output, and hypotension. In patients with severe left ventricular hypertrophy (LVH) due to hypertension or hypertrophic cardiomyopathy, excessive preload reduction can also create subaortic outflow obstruction. For these reasons, the administration of diuretics or venodilators such as nitrates and dihydropyridine calcium channel blockers must be performed with caution. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Choice of medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restoration and maintenance of sinus rhythm is preferred when AF occurs in patients with DHF. When this cannot be achieved, rate control becomes important. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct evidence to support a specific drug regimen to treat DHF is lacking. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic LV diastolic dysfunction is a predictor of future cardiovascular morbidity. Symptomatic patients with DHF experience morbidities (eg, hospitalization for heart failure) at a rate that is virtually the same as that seen in patients with SHF. Mortality rates in both DHF and SHF are high; published data on differences in mortality rates are conflicting. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/1\">",
"      Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004; 351:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/2\">",
"      Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/3\">",
"      Zile MR, Bourge RC, Bennett TD, et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail 2008; 14:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/4\">",
"      Stevenson LW, Zile M, Bennett TD, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail 2010; 3:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/5\">",
"      Zile MR, Adamson PB, Cho YK, et al. Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. J Card Fail 2011; 17:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/6\">",
"      Adamson PB, Zile MR, Cho YK, et al. Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. J Card Fail 2011; 17:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/7\">",
"      Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 2010; 121:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/8\">",
"      Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/9\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/10\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/11\">",
"      . Nonpharmacologic management and health care maintenance in patients with chronic heart failure. J Card Fail 2006; 12:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/12\">",
"      Eberli FR, Apstein CS, Ngoy S, Lorell BH. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 1992; 70:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/13\">",
"      Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006; 114:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/14\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/15\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/16\">",
"      Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/17\">",
"      Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/18\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/19\">",
"      Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992; 117:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/20\">",
"      Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 1993; 22:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/21\">",
"      Bergstr&ouml;m A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/22\">",
"      Andersson B, Caidahl K, di Lenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/23\">",
"      Poulsen SH, Jensen SE, Egstrup K. Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. Am Heart J 1999; 138:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/24\">",
"      Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/25\">",
"      van Veldhuisen DJ, Cohen-Solal A, B&ouml;hm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/26\">",
"      Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/27\">",
"      Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/28\">",
"      Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985; 72:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/29\">",
"      Hopf R, Kaltenbach M. 10-year results and survival of patients with hypertrophic cardiomyopathy treated with calcium antagonists. Z Kardiol 1987; 76 Suppl 3:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/30\">",
"      Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/31\">",
"      Hayashida W, Van Eyll C, Rousseau MF, Pouleur H. Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: modification by long-term enalapril treatment. The SOLVD Investigators. J Am Coll Cardiol 1993; 22:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/32\">",
"      Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/33\">",
"      Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994; 90:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/34\">",
"      Rousseau MF, Gurn&eacute; O, van Eyll C, et al. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohumoral status in patients with ischemic heart disease. Circulation 1990; 81:III123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/35\">",
"      Warner JG Jr, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999; 33:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/36\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/37\">",
"      Little WC, Zile MR, Klein A, et al. Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol 2006; 98:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/38\">",
"      D&iacute;ez J, Querejeta R, L&oacute;pez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/39\">",
"      Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/40\">",
"      Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/41\">",
"      Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/42\">",
"      Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/43\">",
"      Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/44\">",
"      Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/45\">",
"      Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/46\">",
"      Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004; 145:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/47\">",
"      Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/48\">",
"      Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/49\">",
"      Scheuer J, Malhotra A, Hirsch C, et al. Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest 1982; 70:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/50\">",
"      Schaible TF, Ciambrone GJ, Capasso JM, Scheuer J. Cardiac conditioning ameliorates cardiac dysfunction associated with renal hypertension in rats. J Clin Invest 1984; 73:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/51\">",
"      Buttrick PM, Malhotra A, Scheuer J. Effects of systolic overload and swim training on cardiac mechanics and biochemistry in rats. J Appl Physiol 1988; 64:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/52\">",
"      Brenner DA, Apstein CS, Saupe KW. Exercise training attenuates age-associated diastolic dysfunction in rats. Circulation 2001; 104:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/53\">",
"      Spirito P, Pelliccia A, Proschan MA, et al. Morphology of the \"athlete's heart\" assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol 1994; 74:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/54\">",
"      Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/55\">",
"      Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002; 105:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/56\">",
"      Halley CM, Houghtaling PL, Khalil MK, et al. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med 2011; 171:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/57\">",
"      Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/58\">",
"      Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/59\">",
"      Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/60\">",
"      Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 1990; 81:III48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/61\">",
"      Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/62\">",
"      MacCarthy PA, Kearney MT, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ 2003; 327:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/63\">",
"      Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/64\">",
"      Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/65\">",
"      Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001; 38:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/66\">",
"      O'Connor CM, Gattis WA, Shaw L, et al. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/67\">",
"      Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol 2004; 44:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/68\">",
"      Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006; 151:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/69\">",
"      Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/70\">",
"      Persson H, Lonn E, Edner M, et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007; 49:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/71\">",
"      Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/72\">",
"      Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010; 121:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/73\">",
"      Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/74\">",
"      Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/75\">",
"      Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/76\">",
"      Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 2006; 166:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/54/7018/abstract/77\">",
"      Aurigemma GP. Diastolic heart failure--a common and lethal condition by any name. N Engl J Med 2006; 355:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3461 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7018=[""].join("\n");
var outline_f6_54_7018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8053301\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPAIRED RESPONSE TO STRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Choice of medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antiischemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5713896\">",
"      Phosphodiesterase-5 inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Exercise conditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369455524\">",
"      Implantable hemodynamic monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369455754\">",
"      Treatment differences between SHF and DHF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13537491\">",
"      Asymptomatic diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Symptomatic patients (ie, DHF)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26872914\">",
"      - Causes of death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39061108\">",
"      - Morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8053301\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3461|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/42/43693\" title=\"figure 1\">",
"      Regression of LV hypertrophy with antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/7/19580\" title=\"table 1\">",
"      Differential diagnosis of HF-PEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/7/8316\" title=\"table 2\">",
"      ACC AHA Rx HF normal LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/17/41244\" title=\"table 3\">",
"      Manage diastolic HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3461|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/45/32470\" title=\"waveform 1\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9816?source=related_link\">",
"      Calcium channel blockers in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=related_link\">",
"      Cellular mechanisms of diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=related_link\">",
"      Statin therapy in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_54_7019="Bone mineral density T-score";
var content_f6_54_7019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bone mineral density T-score criteria for osteopenia and osteoporosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        T-score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &ge;-1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low bone mass (osteopenia)",
"       </td>",
"       <td>",
"        Between -1.0 and -2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis",
"       </td>",
"       <td>",
"        &le;-2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe (established) osteoporosis",
"       </td>",
"       <td>",
"        &le;-2.5 and fragility fracture",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted for clinical use from the World Health Organization:",
"     <a href=\"file://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf\">",
"      file://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf",
"     </a>",
"     (accessed November 9, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7019=[""].join("\n");
var outline_f6_54_7019=null;
var title_f6_54_7020="Comprehensive geriatric assessm";
var content_f6_54_7020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comprehensive geriatric assessment (CGA) and its implications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Functional status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activities of daily (ADL) and instrumental activities of daily living (IADL)",
"       </td>",
"       <td>",
"        Relation to life expectancy, functional dependence and tolerance of stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Comorbidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of comorbid conditions and comorbidity indices",
"       </td>",
"       <td>",
"        Relation to life expectancy and tolerance of stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folstein Minimental status",
"       </td>",
"       <td>",
"        Relation to life expectancy and dependency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Emotional conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Geriatric Depression Scale (GDS)",
"       </td>",
"       <td>",
"        Relation to survival; may indicate motivation to receive treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Nutritional status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mininutritional assessment (MNA)",
"       </td>",
"       <td>",
"        Reversible condition; possible relationship to survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"1\">",
"        Polypharmacy",
"       </td>",
"       <td>",
"        Risk of drug interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Geriatric syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Delirium, dementia, depression, falls, incontinence, spontaneous bone fractures. Neglect and abuse, failure to thrive.",
"       </td>",
"       <td>",
"        Relationship to survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional dependence",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003; 46:212. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7020=[""].join("\n");
var outline_f6_54_7020=null;
var title_f6_54_7021="Diff dx diffuse myalgia";
var content_f6_54_7021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis and distinguishing features of diffuse myalgia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Distinguishing features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Viral infection",
"      </td>",
"      <td>",
"       Fever, respiratory or gastrointestinal symptoms, viral diagnostic testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bacterial infection",
"      </td>",
"      <td>",
"       Hypotension, rash, heart murmur, leukocytosis, bacteremia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spirochetal infection",
"      </td>",
"      <td>",
"       Rash, Lyme or RPR serology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Non-inflammatory pain syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fibromyalgia",
"      </td>",
"      <td>",
"       Tender points, non-restorative sleep, normal test results",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chronic fatigue syndrome",
"      </td>",
"      <td>",
"       Long-standing, profound fatigue without other explanation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Systemic rheumatic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Polymyalgia rheumatica",
"      </td>",
"      <td>",
"       Acute onset of proximal myalgia, morning stiffness, over age 55, high ESR, prompt improvement with low-dose corticosteroids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Polymyositis/Dermatomyositis",
"      </td>",
"      <td>",
"       Proximal weakness, rash, elevated CK, myopathic EMG, muscle histology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rheumatoid arthritis",
"      </td>",
"      <td>",
"       Chronic, symmetric polyarthritis, positive RF, and/or anti-cyclic citrullinated peptide antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic lupus erythematosus",
"      </td>",
"      <td>",
"       Polyarthritis, rash, nephritis, serositis, positive ANA antibody, anti-double stranded DNA antibody, and/or anti-Smith antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spondyloarthropathy",
"      </td>",
"      <td>",
"       History of psoriasis, colitis, conjunctivitis, urethritis, low back pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vasculitis",
"      </td>",
"      <td>",
"       Multisystem inflammatory disease, palpable purpura, parasthesias, focal neurologic deficit, cavitary pulmonary nodules, active urinary sediment, positive ANCA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Metabolic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Osteomalacia",
"      </td>",
"      <td>",
"       Reduced 25-hydroxy vitamin D",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metabolic myopathy",
"      </td>",
"      <td>",
"       Exercise intolerance, family history, muscle weakness, muscle biopsy results",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Scurvy",
"      </td>",
"      <td>",
"       Petechiae, ecchymoses, follicular hyperkeratosis, corkscrew hairs, vitamin C deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Endocrinologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neuropathic",
"      </td>",
"      <td>",
"       Parasthesias, focal neurologic deficits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypothyroidism",
"      </td>",
"      <td>",
"       Elevated TSH, decreased free T4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adrenal insufficiency",
"      </td>",
"      <td>",
"       Low serum cortisol, 24 hour urine cortisol, and/or abnormal ACTH stimulation test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Medications",
"       </strong>",
"      </td>",
"      <td>",
"       History of new medication use, especially statins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Psychiatric",
"       </strong>",
"      </td>",
"      <td>",
"       Prior history of mood disorder, depressed affect",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ESR: erythrocyte sedimentation rate; CK: creatine kinase; EMG: electromyogram; TSH: thyroid stimulating hormone; T4: thyroxine; RPR: rapid plasma reagin; RF: rheumatoid factor; ANA: anti-nuclear antibody.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7021=[""].join("\n");
var outline_f6_54_7021=null;
var title_f6_54_7022="Fall in thalassemia birthrate";
var content_f6_54_7022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Change in birth rate of thalassemic children after the introduction of preventive programs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cao, A, et al. The Sardinian experience. Semin Hematol 1996; 33:66.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7022=[""].join("\n");
var outline_f6_54_7022=null;
var title_f6_54_7023="Flexion hip deformity in AS I";
var content_f6_54_7023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Masking of flexion deformity of the hip in ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 195px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexion deformity of the hip in ankylosing spondylitis may be masked in the supine position because the patient compensates by an exaggerated lordosis of the lumbar spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_54_7023=[""].join("\n");
var outline_f6_54_7023=null;
